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Chapter 1 
 
General introduction 
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Anatomy of the hippocampus 
The hippocampus is a small, sea-horse-like structure in the medial temporal lobe. It is 
composed of the dentate gyrus, which has a folded appearance, and the cornu ammonis. 
These structures are curved into each other. The hippocampus is divided into the head, body 
and tail. The extraventricular or uncal part of the head is curved posteriorly to the 
parahippocampal gyrus, making the head wider compared to the other parts of the 
hippocampus. Towards the tail the hippocampus becomes thinner, with the tail making a 
curve in transverse direction. On basis of the aspect of the pyramidal neurons the cornu 
ammonis is subdivided into the CA1, CA2, CA3 (and CA4) area. The alveus covers the areas 
intraventricularly. Opposed to the CA1 area the subiculum is located, which connects the 
hippocampus with the entorhinal cortex. 
The hippocampus is lying in the temporal horn, with the head anteriorly bounded by the 
amygdala, and the tail posteriorly disappearing under the splenium. Dorsally, the white 
matter of the medial temporal lobe is present, and ventrally the temporal stem, including the 
tail of the caudate nucleus and stria terminalis. Medially, the entorhinal cortex forms the 
border of the hippocampus. In the ventricle, the hippocampus is usually in part covered by 
the choroid plexus.1 
 
Figure 1: Coronal sections of the hippocampus on T1-weighted MRI. Left upper image most 
anterior, lower image most posterior slice. 
1 = hippocampus; 2 = temporal horn of the lateral ventricle; 3 = entorhinal cortex; 4 = amygdala; 5 = 
temporal stem; 6 = tractus opticus; 7 = choroid plexus; 8 = splenium.   
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Figure 2: Sagital view through hippocampus on T1-weigthed MRI. Upper image is medial 
of lower image. 
1 = head of hippocampus; 2 = amygdala; 3 = tail of hippocampus; 4 = lateral ventricle; 5 = 
parahippocampal gyrus; 6 = subiculum; 7 = temporal horn of the lateral ventricle; 8 = body 
of hippocampus; 9 = fimbria. 
 
 
The hippocampus is vascularized by the posterior cerebral artery, who gives 3 branches 
(anterior, middle and posterior) to the hippocampus, and the anterior choroidal artery (uncal 
branch). The veins of the hippocampus drain into the basal vein.1 
  
The function of the hippocampus has 4 components: learning and memory, regulation of 
emotional behavior, certain aspects of motor control, and regulation of hypothalamic 
functions. 
For learning and memory, the hippocampus is embedded in two pathways: the polysynaptic 
pathway and the direct pathway.2 The polysynaptic pathway gets input from the posterior 
parietal association cortex and neighboring temporal and occipital cortices via the entorhinal 
cortex to successively the dentate gyrus, CA3 area, CA1 area, subiculum, alveus and fimbria. 
From there, the output is projected via the fornix and the anterior thalamic nuclei to the 
posterior cingulated cortex and the retrosplenial cortex. The direct intra-hippocampal 
pathway gets its input from the inferior temporal association cortex, through the perirhinal 
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and entorhinal cortex to the CA1 area. From there, projections are via the subiculum and the 
entorhinal cortex to the inferior temporal association cortex, the temporal pole and the 
prefrontal cortex. The direct pathway is believed to be involved in semantic memory, the 
polysynaptic pathway with episodic and spatial memory. 
Emotional behavior is mainly located in the amygdala, although the hippocampus may 
intervene in the behavior in reaction to pain. As the hippocampus is part of the ventral striatal 
loop, it also plays a role in the control of motor behavior. And last, the hippocampus has 
projections to hypothalamus nuclei and may have influence on the adrenocorticotrophic 
hormone production.1 
 
The hippocampus, Alzheimer’s disease and Mild Cognitive Impairment  
The volume of the hippocampus decreases with age. Volume loss occurs mainly after the age 
of 55 years, although not all reports are unanimous.3-9 
In Alzheimer’s disease (AD), there is more profound atrophy of the hippocampus.4, 10-11 AD 
is a neuro-degenerative disease, with neuronal loss generally assumed to start in the 
entorhinal cortex and the hippocampus, then spreading to the adjacent temporal, parietal and 
frontal neocortex. The histopathology is characterised by neurofibrillary tangles (NFT), 
which are mainly formed by hyperphosphoryated tau-protein, and neuritic plaques (NP), an 
accumulation of amyloid beta. Braak and Braak12 staged AD on the basis of the amount and 
location of mainly NFT and neuropil threads. 
AD is the main cause of dementia in Caucasians. It is a slowly progressive disease 
characterized by multiple cognitive deficits, like memory-loss, aphasia, desorientation, 
visuospatial disturbances and apraxia, causing disturbances in the activities of daily living. 
For research and clinical purposes a working group convened by the NINDS in 1983 
formulated criteria that have been used ever since and have become the standard in clinical 
practice. In essence the criteria are as follows:13 
 
- dementia established by clinical examination and confirmed by neuropsychological 
tests 
- deficits in two or more areas of cognition, including memory impairment 
- progressive worsening of memory and other cognitive functions 
- no disturbances of consciousness 
- age between ages 40 and 90 
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- absence of systemic disorders or other brain disease that in and of themselves could 
account for the progressive deficits in memory and cognition 
 
In fact these criteria simply denote the presence of dementia and, in absence of another 
explanation, consider the dementia to be caused by AD pathology. Also, by the definition of 
at least two domains being affected, the pathology involves more than the hippocampal area 
alone. Because of the above mentioned reasons these criteria are not suitable to detect AD in 
an early stage.  
 
To enable recognition of earlier stages of dementia, an entity called Mild Cognitive 
Impairment (MCI) was coined. It is merely a description of a state with mild disturbances in 
mainly one cognitive domain, without interference of daily life activities. The most widely 
used criteria were formulated by Ronald Petersen and these have been used in clinical 
research and clinical trials already.14 They consist of the following items: 
 
- memory complaint, preferably corroborated by an informant 
- objective memory impairment 
- normal general cognitive function 
- intact activities of daily living 
- not demented 
 
It is widely held that amnestic MCI could signify a pre-stage of dementia, especially AD. 
However, there are other causes of MCI, for example depression or medication.15 It is 
important to identify the subjects with a high risk of dementia, as these subjects usually want 
to be informed about their prognosis, and they may be selected for (pharmacologic) therapy. 
As the hippocampus is atrophied in AD, and is affected early in the disease process of AD, 
hippocampal atrophy might be a good predictor for progression to AD in MCI. 
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Risk factors for hippocampal atrophy 
Previous research has shown several risk factors for AD. Among those are age, APOE ε4, 
high blood pressure and diabetes mellitus (DM). 
High blood pressure has been found to be a significant risk factor for AD in longitudinal 
studies. In the studies based on Honolulu Asia Aging Study (HAAS) higher levels of blood 
pressure were found to increase the risk for clinical AD23 and neuropathologic markers of 
AD.24 In a Chinese population, high blood pressure had an odds ratio of 2 for AD.25 In 
another longitudinal study, high diastolic blood pressure was associated with AD at age 79-
85.26 
The studies on DM are not conclusive. Some longitudinal studies did not find a significant 
relation between DM and AD,27-29 others found an elevated relative risk of 1.5 to 2.30-33 A 
recent systematic review about this association concluded that the evidence supports an 
increased risk for dementia in subjects with DM. This increased risk is also present for AD, 
although the limitations of clinical diagnostic criteria should be considered.34  Recently, an 
elevated relative risk for AD was found in subjects with DM in the absence of the APOE ε4 
allele.35 This is in contrast with an earlier study of Peila et al,33 who found a relative risk of 
5.5 for AD in subjects with DM in the presence of an APOE ε4 allele.   
Several studies have reported on vascular pathology, like white matter hyperintensies 
(WMH) and infarcts on MRI, in subjects with AD.36-38 Also, in neuro-pathological studies, 
vascular lesions are frequently observed in AD brains, and include cerebral amyloid 
angiopathy, microvascular changes, infarction and cerebral hemorrhages.39-41 
 
As AD is thought to be a neuro-degenerative disease, the finding that the presence of vascular 
risk factors increases the risk for AD and vascular pathology in AD, seems remarkable. These 
findings suggest that vascular factors might have a causative role in AD or interact with the 
degenerative process to cause the clinical phenotype. 
 
It is long known that the hippocampus, especially the CA1 area, is vulnerable to ischemia.42-
45
 Also, in studies with rats, hypertension has been shown to decrease hippocampal volume 
and number of neurons in the CA1 area.46,47 Subjects with DM are theoretically at risk for 
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hippocampal atrophy, as the metabolic changes in DM could lead to the formation of NFT 
and NP.48-51  
Taken together, there is reason to doubt the sole neurodegerative nature of hippocampal 
atrophy, and it might well be that vascular factors have a negative influence on hippocampal 
volume. This might have consequences for therapy, for example a more strict regulation of 
blood pressure and glucose in AD patients. Investigating this option would also provide a 
further step in understanding the etiology of hippocampal atrophy. 
 
Measurements for estimating hippocampal volume on MRI. 
Atrophy of the hippocampus can be assessed visually and volumetrically. 
The medial temporal lobe atrophy scale of Scheltens16 is regularly used as a visual method. 
Not only the hippocampus, but the whole medial temporal lobe is assessed on a coronal T1 
weighted MRI sequence. A score from 0 to 4 is applied, dependent on the width of the 
choroid fissure, the width of the temporal horn and the height of the hippocampus. 
This scale was first published in 1992, and is used frequently since. It has been shown to 
correlate well with memory performance16,17 and volumetry,18,19 and can distinguish AD from 
healthy controls.16,20,21 
 
Medial Temporal lobe Atrophy scale 
   
Score 
width of the 
choroid fissure 
width of the 
temporal horn 
height of the 
hippocampus 
0 N N N 
1 ↑ N N 
2 ↑↑ ↑ ↓ 
3 ↑↑↑ ↑↑ ↓↓ 
4 ↑↑↑ ↑↑↑ ↓↓↓ 
↑ indicates increase; ↓ indicates decrease. A score of 0-4 is given 
separately for the left and right side. 
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For assessing the volume of the hippocampus, 3D T1 weighted MRI-images are reformatted 
to oblique coronal plane, perpendicular to the long axis of the hippocampus. The left and 
right hippocampal formations are measured according to criteria published by Jack et al.22 In 
short, the slice on which the hippocampal formation is first visible ventral of the amygdala is 
the most anterior measured. The ventral border is formed by the white matter of the 
parahippocampal gyrus. The dorsal border is formed by the amygdala in the anterior slices; 
more posterior cerebrospinal fluid and choroid plexus form the dorsal border. The slice in 
which the crux of the fornix is visible in its total length is the most posterior slice measured. 
The dentate gyrus, cornu ammonis, subiculum, fimbria and alveus are included in the 
measurements. 
 
Aim of the thesis 
Based on the aforementioned data, we attempted to answer two questions. 
 
Is hippocampal atrophy a good predictor for dementia in subjects with MCI? 
To answer this question, we determined the MTA-score on the MRI of subjects with MCI, 
who visited an outpatient memory clinic, and calculated the hazard ratio of the MTA score 
for dementia after a mean follow-up of 34 months. This study is presented in chapter 2. 
 
What are the risk-factors for hippocampal atrophy? 
We addressed this question in different populations.  
In chapter 3, the association between midlife blood pressure and hippocampal atrophy is 
assessed in a longitudinal, population based study (HAAS). In the analyses is accounted for 
possible confounders, such as socio-demographic characteristics, vascular risk factors and 
vascular damage on MRI, like WMH and lacunes.  
In chapter 4, this association between blood pressure and hippocampal atrophy was 
investigated in subjects with AD. As a senile and presenile onset of dementia might represent 
subtypes of AD, subgroups were made on the basis of the onset of dementia. Also, subgroups 
were made on the presence of WMH, as WMH might be in the causal chain of the association 
of blood pressure and hippocampal atrophy, for example through Wallerian degeneration. 
In chapter 6, the association between DM and hippocampal atrpohy was assessed in the 
longitudinal, population based study (HAAS). Also, other vascular pathologies seen on MRI, 
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like lacunes, WMH and infarcts, were assessed. The hypothesis in this study is that DM leads 
to both vascular as well as neurodegenerative damage in the brain. 
In chapter 7, the association between DM and hypertension and hippocampal atrophy was 
investigated in non-disabled elderly with a wide variety in severity of WMH (LADIS). The 
association was also determined in the different WMH-severity groups and several socio-
demographic and clinical confounders were accounted for.  
The association between hippocampal atrophy and WMH is further investigated in chapter 5, 
were both measures are assessed at baseline and at follow-up in subjects with AD. 
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Chapter 2 
 
Medial temporal lobe atrophy on MRI predicts dementia in patients with 
mild cognitive impairment 
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Abstract 
 
Background 
Although detailed volumetric MRI assessment of medial temporal lobe atrophy (MTA) can 
predict dementia in patients with mild cognitive impairment (MCI) it is not easily applied to 
routine clinical practice. The objective of this study was to test the predictive accuracy of 
visually assessed MTA in MCI patients using a standardized visual rating scale.  
 
Methods 
Seventy-five MCI patients (mean age 63 years) underwent a coronal three-dimensional 
magnetization-prepared rapid gradient echo brain MRI sequence. MTA was rated visually 
using a 5-point rating scale.  
 
Results 
The mean follow-up period for the cohort was 34 months. At follow up, 49% of the enrolled 
MCI patients fulfilled criteria for dementia.  MTA assessed using a standardized visual rating 
scale was significantly associated with dementia at follow-up, with a hazard ratio of 1.5 for 
every point increase in atrophy score (p < 0.001) and of 3.1 for the presence of atrophy based 
on the dichotomised atrophy score (p = 0.003). The predictive accuracy of visually assessed 
MTA was independent from age, gender, education, Mini Mental State Examination score, 
Clinical Dementia Rating Sum of Boxes score, verbal delayed recall, and the presence of 
hypertension, depression, the APOE-ε4 allele and white matter hyperintensities. 
 
Conclusion 
Visual assessment of MTA on brain MRI using a standardized rating scale is a powerful and 
independent predictor of conversion to dementia in relatively young MCI patients. As overlap 
existed in MTA scores between patients with and without dementia at follow-up, the results 
should be interpreted in the light of the odds for the individual patient. 
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Introduction 
Mild cognitive impairment (MCI) is a clinical syndrome with cognitive deficits not severe 
enough to warrant a diagnosis of dementia. A substantial proportion of MCI patients convert 
to dementia, mostly Alzheimer’s Disease (AD), during follow up.1,2 Atrophy of the medial 
temporal lobe, including the hippocampus and entorhinal cortex, is a sensitive marker for 
AD.3-9 Previous studies have shown that the volume of the medial temporal lobe is a marker 
for dementia in patients with MCI.8,10-13 However, volumetric assessment of these structures 
is difficult to apply in routine clinical practice. Reasons include the need for digital MRI-
data, the time consuming nature of region-of-interest analysis, and the fact that automated 
hippocampal volume measurement techniques are not widely available. By contrast the 
assessment of medial temporal lobe atrophy (MTA) using a standardized visual rating scale9 
is a quick and easy measurement, with a comparable predictive accuracy.12-14 Although 
visually rated MTA correctly predicted outcome in 77% of the patients with MCI,12,13 no 
definite conclusion regarding the clinical utility of visual MTA rating can be made. The 
sample size in these studies was small and did not reflect routine clinical practice because of 
the population-based setting or the use of multiple exclusion criteria. In addition, it has not 
been investigated whether qualitative MTA rating has additional predictive value over 
routinely used Mini-Mental State Examination (MMSE) score,15 the Clinical Dementia 
Rating (CDR) Sum of Boxes score,16 verbal delayed recall or APOE genotype, all of which 
are known predictors of cognitive decline.17-20 
The aim of the current study was to test the predictive accuracy for dementia of the visual 
MTA score rated on routinely acquired MRI scans in a large sample of MCI patients from a 
secondary referral setting of a memory clinic. In addition, we investigated whether the 
predictive value of MTA for dementia was independent of the previously mentioned 
parameters. Mild depressive states are frequently seen in the pre-dementia stage of 
neurodegenerative disorders.21 As the relationship between depression and hippocampal 
atrophy is unclear, we also included depression as a confounder in the analyses. White matter 
hyperintensities (WMH) on MRI are also observed in MCI patients and may contribute to 
cognitive decline.22,23 Therefore, WMH was also included as confounder in our analyses. 
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Methods  
Patients  
Patients were selected from subjects that were consecutively investigated for suspected 
dementia at the Geriatric Clinic at Huddinge University Hospital, Stockholm, Sweden. These 
patients were referred by general practitioners and occupational doctors in the greater 
Stockholm area.  
Inclusion criteria were a diagnosis of MCI (see below) at the time of the first visit and a 
baseline assessment between 1992 and 1997. Exclusion criteria were age below 40 years and 
a diagnosis of alcohol abuse according to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th ed. (DSM-IV), criteria.24 A total of 93 patients met these criteria. MRI was 
performed routinely in all patients under the age of 70 years. Above 70 years of age, an MRI 
was done when specifically ordered by the physician for diagnostic purposes. MRI scans 
were available for 19 of 30 patients older than 70 years. In the subgroup of patients older than 
70 years, patients without MRI did not differ from patients with MRI with respect to age, 
gender, years of education, length of follow-up, MMSE, CDR Sum of Boxes, verbal delayed 
recall, hypertension, depression, APOE genotype or decline to dementia (p > 0.1). Twelve 
subjects did not undergo MRI: 10 because they were older then 70 years and 2 because of 
contra-indications for MRI. Patients not undergoing MRI were older (77 vs 63 years; p < 
0.001) and were less often female (25 vs 62% female; p = 0.02) than patients who had an 
MRI. The baseline assessment included routine MRI in all patients under age 70.  
A further six patients were excluded because the follow-up was deemed too short at < 6 
months. Patients lost to follow-up did not differ from the patients with a follow-up with 
respect to age, gender, years of education, MMSE, CDR Sum of Boxes, verbal delayed recall, 
hypertension, depression or APOE genotype (p > 0.3). The final sample thus consisted of 75 
patients. 
 
Baseline assessment 
Baseline assessment consisted of general medical, neurological, psychiatric and 
neuropsychological investigations and brain MRI. General level of cognitive decline was 
assessed by MMSE15 and by CDR.16 APOE genotype was available for 63 patients (84%). 
Patients without APOE genotype assessment were older (69 vs. 62 year; p = 0.02) compared 
to patients with APOE genotype assessment, but did not differ with respect to other variables. 
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A diagnosis of depression24 was considered when the Montgomory and Asberg Depression 
Rating Scale (MADRS)25 score was 7 or higher. In this sample, only mild depression was 
diagnosed, with a maximum MADRS-score of 19.5. 
 
Follow-up assessment  
Routine follow-up appointments were made on a yearly basis until the patient fulfilled 
criteria for dementia or the physician considered that follow-up appointments were no longer 
necessary because cognitive impairment had stabilised or the patient was lost to follow-up. 
The follow-up assessment included a clinical interview, MMSE, CDR rating and 
neuropsychological assessment. No patient received a cholinesterase inhibitor during the 
observation period. 
 
Diagnosis at baseline and follow-up 
Patients were diagnosed with MCI if they performed 1.5 standard deviation (SD) below 
average for their age and education on at least one neuropsychological test, did not fulfil the 
diagnostic criteria for dementia according to DSM-IV criteria,24 and did not have evidence of 
impairment in social or occupational functioning.26 The overall CDR score at baseline was 
0.5 for all patients. The neuropsychological tests were performed by an experienced 
psychologist and comprised five subtests (information, digit span, similarities, block design 
and digit symbol) from the Wechsler Adult Intelligence Scale-Revised,27 Trail Making test A 
and B,28 and free recall and recognition of 12 words from the Stockholm.Geriatric Research 
Center.27,29 
At follow-up, a diagnosis of dementia was ascertained according to the DSM-IV criteria24 by 
an observer blinded to the visual MRI ratings. Probable and possible AD and vascular dementia 
(VaD) diagnoses were made using established criteria.30,31  
 
MRI acquisition 
MRI was performed using a 1.5 T system (Magnetom SP; Siemens, Erlangen, Germany). 
Two sequences were used: routine fast spin-echo proton density/T2 weighted (repetition time 
(TR) 3,500, effective echo time (TE) 19/93 milliseconds) double echo with 19 slices in the 
axial plane (slice thickness = 5 mm, interslice gap = 1.5 mm, field of view = 230 mm 
(rectangular 3/4), matrix = 192 x 256), and coronal (perpendicular to the line intersecting the 
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anterior and posterior commissures in the midsagittal plane) three-dimensional 
magnetization-prepared rapid gradient echo sequence (3D MP-RAGE, TR = 10 milliseconds, 
TE = 4 milliseconds, flip angle = 10°, slice thickness = 2.8 mm). 
 
MRI readings 
MTA was rated on the coronal 3D MP-RAGE images with a slice thickness of 2.8 mm. The 
MTA-scale9 ranges from 0 (no atrophy) to 4 (severe atrophy) and takes into account the 
width of the choroid fissure, the height of the hippocampus, and the width of the temporal 
horn (table 1 and figure 1). The MTA-scale was applied to the right and left medial temporal 
lobe. In the analysis, the summed score of left and right was used as well as the dichotomised 
summed score (no atrophy (score 0 to 2) and atrophy (score 3 and higher)). 
 
Table 1: Scheme of MTA rating. 
  Score width of the 
choroid fissure 
width of the 
temporal horn 
height of the 
hippocampus 
0 N N N 
1 ↑ N N 
2 ↑↑ ↑ ↓ 
3 ↑↑↑ ↑↑ ↓↓ 
4 ↑↑↑ ↑↑↑ ↓↓↓ 
 
↑ indicates increase; ↓ indicates decrease. A score of 0-4 is given 
separately for the left and right side. 
 
 
WMH were scored on the T2-weighted and proton density images. These sequences were 
available for 54 patients. The patients without T2 and proton density images were only 
different with respect to age (66 vs 61 years; p = 0.04) from the patients with these 
sequences. The age-related white matter changes (ARWMC) scale32 was used to score the 
hyperintense deep white matter lesions in 10 different brain-regions, per region ranging from 
0 to 3. For the analysis the scores of all regions were summed.  
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Figure 1: Medial temporal lobe atrophy scale. 
MTA = 0 MTA = 1
MTA = 2 (right side) and 4 (left side)
MTA = 3 MTA = 4
 
The rating from 0 to 4 is displayed; higher scores indicate more atrophy. When 
one score is given, then left equals right.  
 
One rater, who was blinded to all clinical information, performed all ratings. The intra-rater 
agreement for the summed MTA-score, determined on 20 MRI-scans, was good (κ = 0.76) 
and very good (κ = 1) for the dichotomised MTA-score. In an earlier study with four raters, 
the interobserver agreement for the MTA-score varied between a κ value of 0.34 and 0.57 
and between 0.45 and 0.70 for the dichotomised MTA-score.33 The κ value for the summed 
ARWMC-score was very good (κ = 0.82). 
 
Statistical analysis 
The data were analysed using SPSS version 11 (SPSS Inc., Chicago, IL, USA). 
Univariate group differences were analysed by t-tests for continuous variables and χ2 square 
tests with continuity correction or trend analysis for categorical data. The Z-scores of the 
neuropsychological tests, calculated as the difference of the individual score with the mean 
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score divided by the SD, were used to describe the sample in terms of cognitive deficits. 
Because of variability in follow-up length, the predictive accuracy of the MTA score for 
dementia was assessed by Cox regression analysis with follow-up time as time variable and 
conversion to dementia as status variable. In order to determine the odds ratio (OR), 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
of the MTA score for dementia, logistic regression analysis was applied with outcome 
(dementia yes/no) at the latest available follow-up as the dependent variable. A patient was 
considered to have dementia predicted by the logistic regression model if the estimated 
probability for dementia was 0.5. 
To determine the additive value of the MTA score for predicting dementia compared with 
potential other predictors, the MTA score was added together with one of the following 
variables in a Cox regression model: age (in years), gender (% female), MMSE, CDR Sum of 
Boxes, free recall of 12 words from the Stockholm.Geriatric Research Center, presence of 
hypertension (either current or in the past; systolic blood pressure >140 or diastolic blood 
pressure >90), presence of depression, educational level (in years), presence of at least one 
APOE-ε4 allele and the WMH score. The hazard ratios (HR) are presented with 95% CI and 
significance (p value). The same analyses were performed in the subsamples of age above or 
below 70 years.  
 
Results 
After a mean follow-up of 34 months (SD = 20.8, range = 6 to 97 months), 37 (49%) of the 
75 patients had progressed to dementia; these patients are referred to as progressive MCI 
(PMCI). Of those, 26 (70%) had probable AD, 8 (22%) had possible AD and 3 (8%) had 
VaD. Patients who did not convert to dementia during the follow up period were designated 
as stable MCI (SMCI). Of the PMCI, 30% had amnestic MCI, 27% had a deficit in a single 
other cognitive domain, and 43% had deficits in multiple cognitive domains at baseline. In 
the SMCI group, the percentages were 24, 53 and 24. At baseline, patients with PMCI were 
older (p=0.03), had a higher CDR Sum of Boxes score (2.2 vs. 1.4; p = 0.002), had a lower 
MMSE score (26.2 vs 27.5; p = 0.05), had a lower delayed recall score (5.0 vs. 4.1; p = 0.03), 
and had a shorter follow-up length (28.9 vs 39.4 months; p = 0.03) than patients with SMCI 
(table 2). Similar results were obtained if patients with non-AD-type dementia were excluded 
from the PMCI group. 
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Table 2: Baseline characteristics of subjects with Stable MCI and Progressive MCI 
 Stable MCI 
 (n=38) 
Progressive MCI 
 (n=37) 
Age (years) 60.6 
(10.3; range 42-80)) 
65.2 
(7.4; range 53-87)* 
Gender (% women) 53 68 
Follow up (months) 39.4 (23.1) 28.9 (16.7)* 
Education (months) 10.5 (3.3) 9.9 (2.7) 
MMSE at baseline  27.5 (3.1) 26.2 (2.5)* 
CDR sum of boxes  1.4 (0.78) 2.2 (1.2) † 
Verbal delayed recall 5.0 (1.4) 4.1 (1.8)* 
Hypertension (%) 34 19 
Depression (%) 50 33 
WMH score  4.5 (6.1) 4.2 (4.9) 
APOE e4 genotype (%) 42 59 
MTA‡   
0 1 3 
1 2 0 
2 23 8 
3 1 1 
4 11 16 
5 0 2 
6 0 6 
8 0 1 
Dichotomised MTA   
% atrophy 32 70‡ 
 
For age, follow up, education, MMSE, CDR and WMH score the mean (SD) is 
presented. For MTA the numbers per score are presented. 
* p < 0.05; † p = 0.002; ‡ p = 0.001 
 
 
 
Figure 2: Medial temporal lobe atrophy distribution in stable MCI and progressive MCI. 
 
On the y-axis the summed left and right MTA score is displayed in the 2 groups. 
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The distribution of the summed MTA score in the PMCI and SMCI is shown in figure 2. The 
summed MTA score and the dichotomised MTA score were both significantly associated 
with dementia at follow-up in the Cox regression analysis (HR = 1.5 for every point increase 
in summed MTA-score [p < 0.001], and HR = 3.1 for the presence of atrophy according to 
the dichotomised score [p = 0.003]; table 3). Similar results were obtained if patients with 
non-AD-type dementia were excluded from the PMCI group. The OR for progression to 
dementia of the summed MTA score was 1.8 (p = 0.002) for every increase in point of the 
summed MTA score, and 5.1 for atrophy based on the dichotomised score (p = 0.001). The 
sensitivity for detecting patients with dementia at follow-up was 70%, the specificity 68%, 
the PPV 68%, the NPV 70%, and an overall correct classification of 69% for the 
dichotomised score. The positive likelihood ratio for the dichotomised score was 2.19. This 
means that if MTA is present at baseline the pre-test odds changes from 0.96 to 2.2.  
 
Table 3: Cox Regression: univariate analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cox regression with follow-up as time variable and 
outcome (decline to dementia) as status variable.  
* p < 0.05; † p = 0.003; ‡ p < 0.001 
 
Table 3 shows the HRs of the predictor variables for dementia from the univariate Cox 
regression analysis. The results of the bivariate analyses are shown in table 4. None of the 
variables that were added changed the HR of the MTA score for progression to dementia. 
 Hazard Ratio (CI) 
MTA summed score 1.48 (1.19-1.84) ‡ 
MTA dichotomized score 3.05 (1.47-6.41) † 
Age 1.03 (1.00-1.07) 
Female gender  1.30 (0.64-2.64) 
Education 0.93 (0.82-1.06) 
MMSE 0.94 (0.87-1.02) 
CDR Sum of Boxes 1.35 (1.03-1.78)* 
Verbal delayed recall 1.69 (0.89-3.21) 
Hypertension 0.62 (0.27-1.42) 
Depression 0.76 (0.38-1.52) 
APOE ε4 genotype 1.85 (0.91-3.77) 
WMH 1.01 (0.94-1.08) 
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Similar results were obtained if patients with non-AD dementia were excluded from the 
PMCI group. 
In the patients below age 70, the HR of the summed MTA score for progression to dementia 
was 1.41 (95% CI = 1.10-1.80), and for the dichotomised MTA score the HR was 3.25 (95% 
CI = 1.43-7.38). Of the other variables, only age was a significant predictor of decline (HR = 
1.08, 95% CI = 1.01-1.16). In the bivariate analyses, the HR for progression to dementia of 
the dichotomised MTA score did not change by adding the other variables into the model one 
by one. In the subgroup of patients age 70 or older, only the summed MTA score 
significantly predicted progression to dementia (HR = 2.24, 95% CI = 1.21-4.17)). As this 
subgroup only consisted of 18 subjects, we did not perform bivariate analyses. 
 
Table 4: Cox Regression: bivariate analysis 
Variables Hazard Ratio (CI) 
MTA dichotomized score  3.09 (1.28-7.49)† 
Age 1.00 (0.95-1.05) 
  
MTA dichotomized score 3.04 (1.45-6.37)‡ 
Gender 1.26 (0.62-2.57) 
  
MTA dichotomized score 2.88 (1.36-6.08)‡ 
MMSE 0.96 (0.86-1.06) 
  
MTA dichotomized score 2.17 (1.01-4.65)* 
CDR Sum of Boxes 1.25 (0.93-1.67) 
  
MTA dichotomized score 2.41 (1.05-5.52)* 
Verbal delayed recall 1.23 (0.62-2.45) 
  
MTA dichotomized score 3.25 (1.39-7.63)‡ 
Education 0.95 (0.84-1.07) 
  
MTA dichotomized score 3.00 (1.43-6.31)‡ 
Hypertension 0.66 (0.29-1.50) 
  
MTA dichotomized score 2.91 (1.38-6.14)‡ 
Depression 0.87 (0.43-1.76) 
  
MTA dichotomized score 2.84 (1.22-6.58)* 
APOE ε4 1.31 (0.62-2.80) 
  
MTA dichotomized score 3.04 (1.36-6.81)‡ 
WMH 1.00 (0.93-1.08) 
 
Cox regression with follow-up as time variable and outcome 
(decline to dementia) as status variable. 
* p < 0.05; † p = 0.01; ‡ p < 0.01 
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Discussion 
In this prospective, clinically based study, we found that qualitative rating of MTA on MRI 
predicted conversion to dementia in patients with MCI. The predictive value of MTA was 
stronger than and also independent of age, gender, education, MMSE, CDR Sum of Boxes, 
verbal delayed recall, and presence of hypertension, depression, APOE ε4 allele, and WMH.  
The fact that the qualitative rating adequately predicted dementia is in accordance with 
previous smaller studies.12-14 With use of the same MTA-scale, an OR of 12.2 for decline to 
AD was found in an earlier study, with an overall correct classification of 77%.12 Another 
group of investigators,14 who used a qualitative visual rating of the axial aspect of the 
hippocampus on MRI, found an overall predictive accuracy of 91%, with a sensitivity of 91% 
and a specificity of 89%. The reason for the higher accuracy in this study could be that a 
medically healthy group of elderly patients was selected that also had a higher mean age 
compared to our patient sample. 
The predictive accuracy in the present study was comparable to those found in volumetric 
MRI studies. In one study,10 a HR of 1.45 was reported for each 1-unit decrease in the 
hippocampal W-score (increase in atrophy) for crossover to AD. In another study by the same 
research group,19 the W scores of the baseline hippocampal volume also significantly differed 
between the SMCI and PMCI (-0.9 vs –1.7; p = 0.05). In another study,8 the hippocampus and 
the entorhinal cortex were smaller in patients with preclinical AD compared to patients with 
MCI who did not progress, with a somewhat lower overall accuracy of 62% and 59%. The 
volume of the entorhinal cortex was found to predict conversion to AD with an OR of 0.993 
(p = 0.05) for every unit decrease in entorhinal cortex volume and an overall accuracy of 
78%.11 Taken together, these data indicate that both volumetric and qualitative ratings of 
MTA can predict outcome in MCI patients. It should be stated, however, that in all studies, 
including the present one, at the individual level a considerable overlap in atrophy scores was 
found between the patients with stable MCI and the patients who progressed to dementia. 
Therefore, the score should be interpreted in the light of odds for the individual patient. 
An important finding of this study is that visual rating of MTA could predict dementia 
independently from other known predictors of dementia. This is in agreement with a 
volumetric study that addressed this issue, in which the predictive accuracy of hippocampal 
volume was found to be independent of age, APOE genotype, MMSE, CDR and 
hypertension.10 In another study, hippocampal volume as well as the MTA score also 
predicted AD independent from age and delayed recall.13 The CDR sum of boxes was a 
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significant predictor of dementia in the univariate analyses, but lost its significance in the 
bivariate analyses with the MTA score, suggesting that the MTA score is a stronger predictor 
for dementia in this sample. Although the mean CDR sum of boxes of the PMCI was 
relatively high (2.2), these patients were not demented at baseline, as all patients had an 
overall CDR-score of 0.5 at baseline.  
The proportion of patients converting from MCI to dementia was 49% over a mean duration 
of 34 months. This seems rather high but is in keeping with previous studies that have 
reported conversion rates in the same range, 22% to 72% over 3 to 4 years follow-
up,8,10,11,13,19 the range being dependent on the sample selection and age. 
A remarkable observation was that the WMH on MRI as a measure of small vessel disease 
did not predict decline, as opposed to an earlier observation;23 in this study, a significant 
difference in WMH at baseline was found between patients who developed AD and those 
who remained non-demented. A possible explanation for this discrepancy is that in our study, 
76% of the patients had an ARWMC-score of 1 or less in any of the regions. These WMH 
would not be detected on CT, as used in the aforementioned study, in which WMH were found 
in 48% of the patients using another visual rating scale.34 It is likely that the severity and 
distribution of WMH differ between these two patient-populations, which may account for 
the differences in predictive value.   
We used dementia, and not (probable) AD, as outcome measure. The results of the analyses, 
after exclusion of possible AD and VaD, however, were comparable with the total sample. 
Because of the small sample size, separate analyses for VaD were not performed and 
therefore the predictive accuracy of MTA for VaD could not be assessed. It is well known 
however, that MTA is sensitive to, but not specific for, AD.35,36  
Rating of the MTA score yielded a high κ value in this study. As indicated in Methods, prior 
studies have shown lower, but still acceptable, κ scores for intra- as well as for interobserver 
agreement. Variations in reliability of scoring may influence the generalizability of our 
findings. 
A key feature of this study is the clinically based design. The study population is composed 
of all patients with MCI within a certain time period who visited a memory clinic for 
diagnostic purposes, resembling the day-to-day practice of a memory clinic. Moreover, it is a 
broad MCI group, not restricted to pure “amnestic” MCI, and it is a relatively large sample 
compared with other studies in which a visual rating scale was used.12,13 A drawback of this 
clinically based design is the variability of the follow-up period; patients with stable 
cognitive function were discharged, or discharged themselves for several, mainly unknown 
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reasons. The outcome of some patients labeled as SMCI may therefore be uncertain. To 
address this, we performed the analyses using Cox regression to avoid overestimation of the 
associations. The same analyses were run with a logistic regression model (results not 
shown), and similar, even stronger associations were found. Another limitation is the age 
sampling, as patients older than 70 years only underwent MRI in case of diagnostic 
uncertainties. This may have biased the analyses towards higher predictive value, as these 
MRI scans may have been ordered because of suspected dementia. We therefore performed 
the analyses in the sub-sample of patients younger than 70 years of age, who all underwent an 
MRI routinely, and obtained similar results for the independent predictive value of the MTA 
score compared with the total sample. The subsample of patients older than 70 years 
consisted of 18 patients, enabling univariate analyses only. Although the MTA score 
predicted dementia in these older MCI patients the small sample size limits the 
generalizability of the findings. 
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Abstract 
 
Hippocampal atrophy (HA) is usually attributed to the neurofibrillary tangles and neuritic 
plaques of Alzheimer’s disease. However, the hippocampus is vulnerable to global ischemia, 
which may lead to atrophy. We investigated the association of mid-life blood pressure (BP) 
and late-life HA in a sample of Japanese-American men born between 1900 and 1919.  BP 
was measured on 3 occasions between 1965 and 1971. In 1994 to 1996 a subsample 
underwent Magnetic Resonance Imaging (MRI) of the brain. Hippocampal volume was 
estimated by manually drawing regions of interest on relevant scan slices; HA was defined as 
the lowest quartile of hippocampal volume. Also assessed on the MRI were cortical and 
subcortical infarcts, lacunes, and white matter hyperintensities. The risk (OR, 95% CI) was 
estimated for HA associated with systolic (<140 vs > 140 mmHG) and diastolic (<90 vs > 90 
mmHG) BP, and with antihypertensive treatment. Analyses were adjusted for 
sociodemographic factors, other cardiovascular risk factors, apolipoprotein E allele, and 
correlated brain pathology. Those never treated with antihypertensive medication had a 
significantly increased risk for HA (OR = 1.7, 95% CI = 1.12 to 2.65)). The nontreated 
subjects with high systolic BP had an increased risk (OR = 1.98, 95% CI = 0.89 to 4.39) for 
HA. Results were similar for untreated men with high diastolic BP (OR = 3.51, 95% CI = 
1.26 to 9.74). In conclusion, treatment with anti-hypertensive treatment modifies the 
association of BP and HA, such that high levels of BP adversely affect the hippocampus in 
persons never treated with anti-hypertensives. 
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Introduction 
Damage to the hippocampus may cause anterograde and retrograde memory impairment.1 
The hippocampus and surrounding areas within the medial temporal lobe are typically 
involved in Alzheimer’s disease (AD),2-6 but are also affected in other dementias, such as 
vascular dementia (VaD).7-10 In AD, hippocampal atrophy (HA) is usually attributed to the 
deposition of neurofibrillary tangles and neuritic plaques.11,12 However, the hippocampus, 
particularly the CA1 area, is vulnerable to global ischemia. This vascular damage, leading to 
selective capillary abnormalities, neuronal necrosis, microglial and macrophage formation13-
16
 may contribute to HA in both AD and VaD.  
For these reasons, we investigated the association of high blood pressure (BP) and HA in a 
sub-sample of Japanese American men participating in the longitudinal community-based 
Honolulu Aging Asia Study (HAAS). Previously in this cohort, we found that hypertension 
in midlife increased the risk for late-life cognitive impairment, AD and VaD and for 
neuropathologic markers of AD.17-20 Results, particularly for the clinical end points of AD, 
were strongest in those never treated for hypertension.  
 
Methods 
The design of the HAAS has been described elsewhere.22 The original cohort included 
Japanese-American men born between 1900 and 1919 who underwent 5 exams (examination 
1: 1965-1968; examination 2: 1968-1970; examination 3: 1971-1974; examination 4: 1991-
1993; examination 5: 1994-1996). At each examination, clinical measures were made and 
sociodemographic and medical conditions assessed.  
 
Dementia, blood pressure and treatment 
At exams 4 and 5, cognitive status was tested with the Cognitive Abilities Screening 
Instrument (CASI)23 and prevalent (examination 4) and incident (examination 5) dementia 
was ascertained.22;24 Diagnostic and Statistics Manual of Mental Disorders- revised (DSM-
IIIR) criteria25 were applied for dementia, National Institute of Neurologic Diseases and 
Stroke—Alzheimer’s Disease and Related Disorders26 for AD, and the State of California 
Alzheimer’s Disease Diagnostic and Treatment Centers for VaD.27 Stroke was identified 
through the ongoing hospital surveillance system. Apolipoprotein E (ApoE) genotyping was 
performed at examination 4.28 
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We categorized BP, measured at the 3 midlife exams, as follows17: systolic BP (SBP): low 
(< 110 mmHg), normal (110 to 139 mmHg) and borderline/high (≥ 140 mmHg); diastolic 
BP (DBP): low (< 80 mmHg), normal (80 to 89 mmHg) and borderline/high (≥ 90 mmHg). 
Subjects were further classified as (n)ever treated with anti-hypertensive medication or 
report of treatment at any of the first 4 examinations. A new variable was created that 
combined treatment and mid-life BP. The BP categories were collapsed into two categories: 
SBP: > 140 mmHg vs < 140mmHg; DBP: > 90 mmHg vs < 90 mmHg. These BP categories 
were combined with treatment status (yes/no) to form four groups: never treated - normal, 
treated - normal, never treated - high, treated - high. For the analyses, the never treated - 
normal BP served as the reference group. Isolated high SBP was defined as SBP ≥ 140 
mmHg with a DBP < 90 mmHg. Isolated high DBP was defined as DBP ≥ 90 mmHg with a 
SBP < 140 mmHg. These categories were also combined with treatment status in the same 
way as described above. 
 
Magnetic Resonance Imaging substudy 
At exam 5, an MRI study was conducted on a sub-sample,29 including a ~10% random 
sample and a randomly selected oversample of those with prevalent dementia, those who 
scored poorly on the CASI but did not meet criteria for dementia, those with apoE ε4 
genotype, and those with clinical stroke.  
Scans were acquired with a GE Signa Advantage, 1.5 Tesla machine. The acquisition 
protocol included a T1 weighted sagital sequence, a three-dimensional coronal spoiled 
gradient echo sequence (SPGR), and axial T2 and proton density weighted fast-spin echo 
sequences.  
The coronal SPGR sequence was reformatted to oblique coronal, perpendicular to the long 
axis of the left hippocampus. The left and right hippocampal formations were measured 
according to published criteria30 and corrected for the total intracranial volume. One reader 
performed all measurements. The intra-class correlation coefficient for the intra-reader 
agreement of the hippocampal volume (HV) was 0.97.  Number of lacunes, cortical and 
subcortical infarcts,31 and white matter hyperintensities (WMH), graded on a scale of 0 to 
9,32 were determined.  
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Measures of confounding variables 
Besides the variables used in sample selection, other possible confounders of the association 
between HA and BP were considered: education (<7 years, 7 to 9 years, > 9 years 
[reference]), smoking (never [reference], current and past) and daily alcohol use (none 
[reference], less than one drink, one or two drinks, more than 2 drinks per day).  
 
Analytical sample 
621 MRI scans were collected, and 543 MRI scans could be processed successfully for all 
relevant variables. The MRI sample is somewhat older (81.6 vs 79.6 years; p < 0.001) and 
had fewer years of education (10.3 vs 10.9 years; p = 0.01) compared to the total sample at 
examination 5, but did not differ with respect to BP.  
 
 
Statistical analyses 
We examined the relationship between BP and HV. We also created two groups, by 
dichotomising HV at the 25th percentile; < 25 percentile was defined as HA. ANOVA was 
used to test age-adjusted differences in HV by subject characteristics; Mantel-Haenszel test 
was used to test for differences in HA. We used a linear regression approach for HV and 
logistic regression approach for HA. Separate adjusted models were run for SBP and DBP, 
treatment status, and the combined BP/treatment variables. Three models were estimated: 
model 1 adjusted for age and education; model 2 also included apoE genotype, dementia 
status, smoking and alcohol use; model 3 we added other pathologies related to both BP and 
HA, including lacunes, WMH, cortical and subcortical infarcts. The interaction between high 
and normal levels of BP and treatment was tested by entering into model 1 the cross product 
between the 2 variables. Since the conclusions were similar, we present the logistic 
regression association (OR and 95% confidence interval [CI]) of BP with HA. 
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Table 1: Demographic data of MRI participants: the HAAS 
 Characteristic 
% of 
subjects 
hippocampal 
volume(mm3) 
% in lower quartile of 
hippocampal volume 
 (n=543)  mean (SD)  
Age (years)    
<80  49.4 5583 (786)* 16.4* 
>80  50.6 5202 (842) 32 
Education (years)    
< 7 9.6 5120 (905) 34.6 
7-9  38.3 5369 (830) 24.5 
>9  52.1 5455 (820) 22.3 
ApoE genotype    
33 56.2 5344 (842) 25.7 
24, 34, 44  36.1 5484 (821) 21.4 
22, 23  7.7 5314 (843) 26.2 
Diagnosis    
Not demented 78.8 5560 (752) 16.8 
AD 9.2 4631 (820) 62.0 
AD+ 4.2 4697 (888) 56.5 
VaD 4.1 4868 (810) 40.9 
Other dementias 3.7 5029 (822) * 35* 
Smoking    
Never 40.1 5313 (868) 25.2 
 Past 31.9 5473 (773) 22.0 
Current 23.2 5426 (840) 23.8 
Alcohol (drinks/day)    
None 27.8 5394 (891) 21.9 
<1 47.3 5434 (801) 23.0 
1-2 8.3 5229 (886) 31.1 
>3 12.3 5373 (763) 25.4 
WMH Grade    
1-2 53.0 5470 (815) 20.8 
 3 19.9 5328 (868) 26.9 
>4 27.1 5280 (844) 29.3 
Lacunes    
0 56.4 5358 (856) 25.8 
1-2 32.2 5428 (803) 22.3 
3-5 11.4 5443 (834) 22.6 
Subcortical infarcts    
0 96.3 5388 (831) 24.1 
1-2 3.7 5454 (992) 30.0 
Cortical infarcts    
0 91.0 5395 (828) 23.7† 
1-4 9.0 5341 (926) 30.6 
WMH = white matter lesions  
Age adjusted p-values compared to the normal reference group: 
 * = <0.001; † = <0.05 
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Results 
The mean age of the MRI sample was 81.6 years (SD = 5.0). In this sample, the left 
hippocampal volumes were smaller than the right hippocampal volumes (mean difference = 
138 mm3; SD = 270; p < 0.001). The results of the analyses for the left, right and total HV 
did not differ, so we only present the analyses with the total HV. HV were significantly 
higher in non-demented men compared those with AD, AD with cardiovascular disease, and 
VaD (table 1). HV was also significantly related to the CASI-score (p-trend < 0.001; table 2). 
 
Table 2: Mean CASI-score per quartile of the hippocampal volumes: the HAAS 
 
Quartile of 
hippocampal 
volume 
CASI-score 
(mean (SD)) 
1 64.1 (20.6) 
2 72.9 (13.7) 
3 77.1 (11.5) 
4 79.6 (11.8) 
The age-adjusted test of trend is p< 0.001. 
 
 
The prevalence of lacunes and infarcts was high. There was 3.7% with 1 or more subcortical 
infarcts, 9.0% with 1 or more cortical infarcts, and 47% had 1 or more lacunes. There was 
27.3% with a WMH score of 4 or higher. There were no significant differences in HV 
between the subjects with and without subcortical infarcts, cortical infarcts, lacunes or 
WMH. However, the percentage of subjects with HV in the lowest quartile was higher in the 
subjects with cortical infarcts compared to the subjects without cortical infarcts (table 1).  
In the total sample, DBP and SBP were not significantly associated with HA. Those not 
treated with antihypertensive medication, however, had a significantly increased risk for HA 
(OR = 1.7, 95% CI = 1.12 to 2.65), adjusting for age, education, ApoE genotype, smoking, 
alcohol use and dementia. Treatment history modified the association between BP and HA. 
Compared to the never treated - normal group, the treated men with normal or high SBP had 
a reduced risk (OR = 0.56, 95% CI = 0.33 to 0.97 and OR = 0.74, 95% CI = 0.42 to 1.32 
respectively) for HA; the non-treated high SBP group had an increased risk (OR = 1.98, 95% 
CI = 0.89 to 4.39) for HA. 
This same trend is seen in the DBP groups: the treated subjects with normal or with high 
DBP had a reduced risk (OR = 0.69, 95% CI = 0.43 to 1.12 and OR = 0.50, 95% CI = 0.24 to 
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1.04 respectively) and the untreated subjects with high DBP had an increased risk (OR = 
3.51, 95% CI = 1.26 to 9.74) for HA compared to the non-treated subjects with normal DBP.  
 
 
Table 3: Late age hippocampal volume and atrophy by mid-life blood pressure and treatment 
group: the HAAS 
 
 
 
Group Subjects  
(%) 
Mean 
hippocampal 
volume 
(mm3 (SD)) 
% in lower 
quartile of 
hippocampal 
volume 
    
SBP (mmHg)    
   <140 74.2 5402 (840) 23.3 
   >140 25.8 5358 (826) 27.1 
    
DBP(mmHg)    
   <90 83.1 5392 (860) 25.1 
   >90 16.9 5384 (712) 20.7 
    
Treated with anti-
hypertensives 
   
   No 52.3 5343 (898) 28.6 
   Yes 47.7 5448 (757) 19.3 
    
Not-treated ‘normal’ SBP 46.0 5369 (903) 26.8 
Treated ‘normal’ SBP 28.0 5466 (717) 17.1 
Not-treated high SBP 6.3 5147 (845) 42.4 
Treated high SBP 19.7 5423 (813) 22.4 
    
Not-treated ‘normal’ DBP 48.8 5363 (902) 27.5 
Treated ‘normal’ DBP 34.1 5441 (790) 21.1 
Not-treated high DBP 3.5 5045 (792) 44.4 
Treated high DBP 13.6 5466 (671) 14.9 
 
SBP = systolic blood pressure. DBP = diastolic blood pressure. 
Treatment refers to high blood pressure treatment. 
‘Normal’ SBP is <140 mmHg; High SBP is >140 mmHg; ‘Normal’.  
DBP is < 90 mmHg; High DBP is > 90 mmHg. 
 
 
The interaction between DBP and treatment was significant (p = 0.03) as was the interaction 
between SBP and treatment (p = 0.02). Adjusting for lacunes, subcortical infarcts, cortical 
infarcts or WMH did not change these associations (table 4). Regression analyses with only 
the non-demented subjects resulted in essentially the same associations; the OR of untreated 
high DBP was somewhat higher (OR = 4.76, 95% CI = 1.56 to 14.5).   
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Isolated high SBP and isolated high DBP were not significantly associated with HA. 
Compared to those with untreated normal blood pressure, there were no significant 
differences in HA in men with isolated systolic blood pressure who were treated (OR = 0.9, 
95% CI = 0.45 to 1.81) or not treated (OR = 1.21, 95% CI = 0.49 to 3.02). Similarly, the risk 
for isolated DBP in treated (OR = 0.17, 95% CI = 0.02 to 1.30) and untreated (OR = 0.02, 
95% CI = 0.44 to 8.42) men did not differ from those with untreated normal BP.  
 
Discussion 
In this longitudinal, prospective, population-based study we found that men never treated for 
high mid-life BP had an increased risk for HA compared to never treated men with normal 
mid-life BP. Treatment with anti-hypertensive medication reduced the risk associated with 
high BP. Several studies show that more hippocampal atrophy is associated with poorer 
cognitive function, AD, as well as other causes of dementia.3-6;9;10;33-46 
This study has several strengths. One is the community-based sample, which has a wide 
range of BP and includes persons who have never been treated with antihypertensive 
medication despite high levels of SBP or DBP in midlife. Second, BP was measured in 
midlife, years before the onset of dementia. This is crucial, because dementia, as well as 
other factors more prevalent in old age, may lead to a lowering of BP. This decline may 
begin many years prior to the clinical detection of dementia. Also, BP was measured at 3 
different time points, 3 times at each examination, so a reasonable estimation of average BP 
was obtained. Furthermore, in the analyses, we controlled for WMH and infarcts, which may 
mediate or confound any associations of HA to BP. Another important advantage of this 
study is that one rater performed the quantitative measure of the HV, with a high intrarater 
reliability.  
However, we might have missed subjects who were treated and than stopped treatment 
between exams 3 and 4. Further, the men were very old at the time the MRI was made. As 
subjects with longstanding hypertension are likely to die at a younger age because of the 
adverse effects of hypertension on other organs, the effects of high BP on the hippocampus 
may be underestimated. In addition, within subgroups that were oversampled, those in the 
MRI sample may have been slightly healthier compared to subgroup members randomly 
selected but who did not participate. 
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Table 4: Risk (odds ratio (95% confidence intervals)) for late-age hippocampal atrophy by mid-life blood 
pressure and treatment with anti-hypertensives: the HAAS. 
 
Group Model 1 Model 2 Model 2 
 + lacunes 
Model 2 
+ subcort inf 
Model 2 
 + cort inf 
Model 2 
 + WML 
       
Not –treated ‘normal’ SBP 1 1 1 1 1 1 
Treated ‘normal ‘ SBP 0.58 
(0.35-0.98) 
 
0.56 
(0.33-0.97) 
0.60 
(0.35-1.02) 
0.56 
(0.33-0.96) 
0.55 
(0.32-0.94) 
0.56 
(0.33-0.96) 
Not treated high SBP 1.74 
(0.81-3.74) 
 
1.98 
(0.89-4.39) 
2.14 
(0.96-4.79) 
1.90 
(0.85-4.24) 
2.05 
(0.93-4.55) 
1.89 
(0.85-4.22) 
Treated high SBP 0.79 
(0.46-1.37) 
 
0.74 
(0.42-1.32) 
0.77 
(0.43-1.38) 
0.73 
(0.41-1.30) 
0.73 
(0.41-1.31) 
0.73 
(0.41-1.30) 
       
Not treated  ‘normal’ DBP 1 1 1 1 1 1 
‘Treated’ ‘normal’ DBP 0.73 
(0.46-1.14) 
 
0.69 
(0.43-1.12) 
0.71 
(0.44-1.15) 
0.69 
(0.43-1.12) 
0.68 
(0.42-1.09) 
0.70 
(0.43-1.13) 
Non treated high DBP 2.81 
(1.05-7.55) 
 
3.51 
(1.26-9.74) 
3.59 
(1.28-10.0) 
3.28 
(1.17-9.19) 
3.58 
(1.29-9.94) 
3.51 
(1.27-9.75) 
Treated high DBP 0.53 
(0.26-1.07) 
0.50 
(0.24-1.04) 
0.52 
(0.25-1.10) 
0.49 
(0.23-1.02) 
0.49 
(0.23-1.02) 
0.48 
(0.23-1.01) 
 
SBP = systolic blood pressure; DBP = diastolic blood pressure. Treatment refers to high blood pressure treatment. ‘Normal’ SBP is <140 
mmHg; High SBP is >140 mmHg. ‘Normal' DBP is < 90 mmHg; High DBP is > 90 mmHg. 
 
Model 1: adjusted for age and education  
Model 2: adjusted for age, education, apoe genotype, smoking, alcohol and dementia. 
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High BP was a significant risk factor for dementia in longitudinal studies.21;47 In the studies 
based on HAAS data we have found that higher levels of BP increased the risk for cognitive 
impairment,17,19 clinical AD and VaD,18 and neuropathological markers of AD.20 In the 
clinical data these associations were modified by treatment status, whereby the greatest risk 
for adverse brain events was in those never treated with antihypertensives. The finding of a 
BP and treatment interaction on the risk for HA is consistent with these previously published 
analyses based on different measures of brain pathology. 
The studies of Amenta et al and Sabbatini et al are of interest in the light of our findings.48;49 
In both studies, a group of normal rats and a group of genetically manipulated hypertensive 
rats were investigated. In the study of Amenta et al, hypertensive rats had reduced BP and 
tunica media thickness of intracerebral arteries after treatment with nicardipine, a calcium-
channel blocker. In the hippocampus of the hypertensive rats, the number and size of neurons 
in the CA1 field were reduced compared to the normal rats, and the number of neurons in the 
CA1 field was increased after treatment with nicardipine. The study of Sabbatini et al also 
showed that the volume of hippocampi in hypertensive rates was smaller, and the volume 
increased when the rats were treated with antihypertensives. This volume decrease and 
increase was mostly explained by volume changes in the CA1 field. The treatment effects 
found in these animal studies are consistent with our finding that treatment was associated 
with a protective effect on HV. In the HAAS we do not have information on the type of 
antihypertensive medication that was taken nor is it known whether the treatment effect in 
the animals studies were specific for the nicardipine. Further research in this area is 
warranted. 
Also of interest in light of our findings is the study of de Jong et al,16 in which chronic brain 
hypoperfusion was found to cause selective capillary abnormalities in the CA1 region in rats, 
and the severity of capillary abnormalities was significantly related to cognitive performance. 
It is possible that the capillary changes precede neuronal changes and atrophy, and 
hypotension (i.e., caused by long-standing hypertensive vascular changes) plays a role in the 
atrophy of the hippocampus. 
We took vascular damage in the brain into account, because it may confound or mediate the 
association between the HV and BP. Lacunes, subcortical and cortical infarcts, and WMH 
did not change the associations of interest. Earlier reports suggest that small vessel disease 
may be closely associated with hippocampal volume loss39 or hippocampal hypoperfusion.50 
In this study, correction for WMH and lacunes did not alter the relation we found between 
BP/treatment and HV. This is in contrast to the hypothesis that hypertension influences the 
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WMH and hippocampus through similar mechanisms. That the mechanism of BP on HV is 
probably different from the hypertensive effect on WMH is supported by the findings of Fein 
et al.,51 who found that WMH correlated with cortical atrophy, but not specifically with HA. 
In conclusion, high levels of untreated BP was associated with HA. Treatment with anti-
hypertensive treatment may modify this association.  
 
Perspectives 
HA is usually classified as a pure neuro-degenerative process. This study shows that a risk 
factor for vascular damage, hypertension, may also be associated with HA. The precise 
mechanism is unknown. Our findings should stimulate more studies to explore the effect on 
hippocampal atrophy of elevated levels of BP and of antihypertensive treatments. Also, other 
clinical and experimental studies are needed to delineate the pathophysiology of how 
elevated blood pressure modifies brain structure and risk for neurodegeneration. Such studies 
may help us to understand the etiology of the prevalent types of late-life cognitive disorders. 
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Abstract 
Background 
Vascular factors are recognized as important risk factors for Alzheimer’s disease, although it 
is unknown whether these factors directly lead to the typical degenerative pathology such as 
medial temporal lobe atrophy. We set out to investigate the relation between blood pressure 
and medial temporal lobe atrophy in patients with senile and presenile Alzheimer’s disease 
with or without white matter hyperintensities.  
 
Methods 
We determined the relation between blood pressure and pulse pressure and medial temporal 
lobe atrophy on MRI in 159 patients with Alzheimer’s disease, stratified on white matter 
hyperintensities and age at onset of dementia.  
 
Results 
There was a linear relation between systolic blood pressure and pulse pressure (both in 
tertiles) and the severity of medial temporal lobe atrophy (ptrend = 0.05 and ptrend = 0.03, 
respectively). A significant relation was found between pulse pressure (β = 0.08 [95% CI = 
0.00 to 0.15; p = 0.05] per 10 mmHg) and (borderline significant) systolic blood pressure (β = 
0.05 [95% CI = -0.01 to 0.11; p = 0.1] per 10 mmHg) and medial temporal lobe atrophy. 
White matter hyperintensities and age-stratified analysis revealed a significant association 
between systolic blood pressure and pulse pressure and medial temporal lobe atrophy, only in 
the subsample with white matter hyperintensities and in the subsample with a senile onset of 
dementia. The relations were independent of severity of dementia and diabetes mellitus.  
 
Conclusions 
Systolic blood pressure and pulse pressure are associated with medial temporal lobe atrophy 
in Alzheimer’s disease, especially in the presence of white matter hyperintensities and in 
patients with a late onset of dementia. Our finding may be another step in providing a 
rationale on how vascular factors could ultimately result in Alzheimer’s disease. 
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Introduction 
High blood pressure (BP) and atherosclerosis are increasingly being recognized as risk factors 
for Alzheimer’s disease (AD).1-3 The structural brain changes caused by these risk factors, 
such as white matter hyperintensities (WMH), lacunar infarcts and (sub)cortical atrophy can 
only in part explain the clinical spectrum of AD. Brain changes of vascular origin cannot 
account for the typical memory dysfunction in AD, which is thought to be related to medial 
temporal lobe atrophy (MTA). MTA is a hallmark of the pathology of AD and has proven to 
be a sensitive marker for the future development of AD when present on MRI scans.4-8   
Recent studies have found a relation between increased BP levels and AD-related 
neuropathological changes, including an increased number of neuritic plaques (NP) and 
neurofibrillary tangles (NFT) in the entorhinal cortex and hippocampus of non-demented 
individuals.9,10 We therefore wanted to investigate the relation between systolic blood 
pressure (SBP), diastolic blood pressure (DBP) and pulse pressure, as an indicator of 
atherosclerosis, and MTA in patients with AD. 
A previous study from our group showed that WMH are related to MTA.11 In order to 
investigate whether WMH are intermediate in the relation between BP en MTA, we stratified 
on the presence or absence of WMH. We also performed age-stratified analysis since there is 
ample evidence that presentation of symptoms and the MRI characteristics differ between a 
presenile and a senile onset of AD.12-14 Since dementia severity and diabetes mellitus (DM) 
are both related to the determinant and the outcome (and are not in the causal chain), they 
may act as a confounder3,15-22 and were both adjusted for in the analyses.  
 
Methods 
Patients 
Patients were selected from individuals that were consecutively investigated for suspected 
dementia at a secondary/tertiary referral Alzheimer Center. We identified 159 patients with 
AD in a 2-year period, who underwent a standardized work-up, involving history taking, 
physical and neurological examination, blood tests (erythrocyte sedimentation rate, 
haemoglobin, white cell count, serum electrolytes, glucose, urea, creatinine, liver function 
tests, Thyroid Stimulation Hormone and free thyroid hormone, vitamin B1 and B6 levels, 
syphilis serology), Mini Mental State Examination (MMSE), neuropsychological 
examination, MRI of the brain and a quantitative EEG. Final diagnosis was based upon a 
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consensus meeting, attended by at least a neurologist, neuropsychologist, radiologist, clinical 
neurophysiologist, geriatrician and specialized nurse, where all the available clinical data and 
the results of the ancillary investigations were considered. A diagnosis of probable AD was 
based upon the NINCDS-ADRDA criteria.23  
 
MRI 
All patients underwent cranial MR imaging including coronal T1-weighted and transverse 
proton density (PD) or fluid attenuated inversion recovery (FLAIR) images on a 1.0-tesla 
scanner (Impact, Siemens AG, Germany) or a 1.5-tesla scanner (Vision, Siemens AG, 
Germany). Slice thickness of the transverse PD and FLAIR was 5 mm with an inter-slice gap 
of 20.0%. Slice thickness of the coronal T1 weighted sequence was 1.5 mm without inter-
slice gap.  
 
MTA and WMH rating scale 
MTA was rated on the T1-weighted coronal images using the MTA-scale17: this scale ranges 
from 0 (no atrophy) to 4 (severe atrophy), and takes into account the width of the choroid 
fissure, the height of the hippocampus, and the width of the temporal horn. The MTA-scale 
was applied to the right and left medial temporal lobe and the mean of these two measured 
was used in the analysis. Previous studies showed a fair to moderate inter-rater agreement (κ 
value 0.3 to 0.6)24 and a good intra-rater agreement with a κ value of 0.825 for the MTA score. 
The MTA is significantly correlated with memory function16,17 and shows a good relation with 
volumetry.26,27 MTA is also a predictor of AD in patients with mild cognitive impairment.7,8,25 
WMH were rated with the age-related white matter changes (ARWMC) rating scale.28 In 
short: WMH on MRI are defined as ill-defined hyperintensities of ≥ 5 mm on PD or FLAIR 
images, and are rated on a four-point scale in five different regions in the left and right 
hemisphere separately: (1) the frontal area; (2) the parieto-occipital area; (3) the temporal 
area; (4) the infratentorial area and (5) the basal ganglia and scored semi-quantitatively as 0 
(no WMH), 1 (single or multiple focal lesions ≥ 5 mm), 2 (beginning of confluence of 
lesions) or 3 (confluent WMH). Total degree of WMH was calculated by adding the region-
specific scores of both hemispheres (range 0-30). WMH could not be rated in 8 patients due 
to poor scan quality (movement artefacts). 
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One rater, blinded for BP measurements, scored the WMH and the MTA with good to 
excellent intra-rater agreement (κ = 0.70-1.0 and κ = 0.6-0.8, respectively).  
 
Blood pressure  
BP level was based on a single measurement with the patient in sitting position. The first and 
the fourth Korotkoff tone were used for the SBP and DBP, respectively. Pulse pressure was 
defined as the difference between SBP and DBP. Information on treatment for high BP was 
collected by a structured interview. 
 
Other variables 
Global dementia severity was estimated with the MMSE.29 Presence of DM was defined by 
the use of oral anti-diabetics or insulin, and was previously assessed by the general 
practitioner or by a specialist in internal medicine by applying standard methods.30 In the 
present sample, no subjects with newly discovered DM were included.  
 
Statistics 
Age-adjusted differences in subject characteristics were examined across subgroups using 
analyses of variance if the characteristic was continuously distributed and with Mantel-
Haenszel test if it was categorical. We calculated regression coefficients (with 95% CIs) by 
means of age and sex adjusted multiple linear regression analysis to quantify the relation 
between BP, pulse pressure and MTA. The interaction between SBP and WMH was tested by 
entering the cross product between the two variables into the model. Likewise, the interaction 
between pulse pressure and WMH, DBP and WMH, SBP and age at onset of dementia, DBP 
and age at onset of dementia, and pulse pressure and age at onset of dementia was tested. 
Secondly we investigated the relation between BP and pulse pressure and MTA stratified on 
the presence of WMH. Total WMH was dichotomised into no WMH (score 0) and any WMH 
(score > 0). Thirdly, we stratified on the age at onset of dementia. Presenile onset of AD was 
defined as the first symptoms of cognitive decline occurring before the age of 65 years.12,31  
In order to gain statistical power and to increase contrast between groups, means of the left 
and right MTA scores were divided into 4 categories11: score 0-0.5 (n = 23); 1-1.5 (n = 66); 2-
2.5 (n = 56); 3-4 (n = 14). Tests for trend were calculated by inserting tertiles of BP and pulse 
pressure as continuous variables in the multivariate models. 
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These relations may be confounded by dementia-severity or DM. We therefore included the 
MMSE and DM as possible confounders in the models. 
 
 
Table 1: Baseline characteristics for the whole study population  
and stratified on WMH and age. 
 
 Total sample 
(n=159) 
 WMH absent 
(n=108) 
WMH present 
(n=43) 
 Presenile 
(n=66) 
Senile  
(n=93) 
Age (years) 68.3 (8.8)  67.1 (8.9) 71.3 (8.0)a  59.2 (5.4) 74.5 (4.2) b  
Sex (% female) 49.7  50.9 48.8  55.4 45.7 
Duration of symptoms 
(years) 
2.6 (1.9)  2.6 (1.9) 2.6 (1.6)  2.9 (2.1) 2.4 (1.7)  
MMSE  20.7 (5.1)  20.6 (5.2) 21.1 (4.8)  19.0 (4.6) 21.7 (5.1)c  
SBP (mmHg)  149.2 (22.5)  149.1 (20.9) 152 (25.6)  141.8 (20.7) 154.4 (22.3)b  
DBP (mmHg) 86.0 (11.4)  86.5 (11) 85.9 (11.6)  85.8 (11.8) 86.1 (11.1) 
Pulse pressure (mmHg) 63.2 (17.7)  62.6 (16.0) 66.1 (20.6)  56 (14.5) 68.3 (18.0)b  
Treatment for high BP 
(%) 
19.0  14.0 32.6d   12.5 23.4 
DM (%) 5.6  5.9 6.1  2.0 8.1 
WMH-score         
   ARWMC = 0 (%) 71.5  100 0  82.3 64.0e 
   ARWMC > 0 (%) 28.5  0 100  17.7 36.0 
Mean MTA score (%)        
   0-0.5  14.5  18.5 7.0f  19.7 10.8g 
   1-1.5 41.5  47.2 27.9  51.5 34.4 
   2-2.5 35.2  28.7 55.8  24.3 43.0 
   3-4 8.8  5.6 9.3  4.5 11.8 
Baseline characteristics of the study population, stratified on WMH and on the age of onset of dementia. Values 
represent means (SD) or percentages. WMH rating missing in 8 patients. Age-adjusted differences in subject 
characteristics were examined across subgroups using analyses of variance if the characteristic was continuously 
distributed and with Mantel-Haenszel test if it was categorical. 
WMH- = the sub-sample without WMH; WMH+ = the sub-sample with WMH; Presenile = the sub-sample with 
a presenile onset of dementia; Senile = the sub-sample with a senile onset of dementia; WMH-score = total 
ARWMC-score.  
a: p = 0.009 compared to WMH-; b: p < 0.001 compared to presenile; c: p = 0.004 compared to presenile; d: p = 
0.01 compared to WMH-; e: p = 0.02 compared to presenile; f: p = 0.002 compared to WMH-; g: p = 0.002 
compared to presenile 
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Results 
Baseline characteristics are listed in table 1. Mean age was 68.3 years (range 49 to 89 years), 
almost 50% of the subjects were female. High DBP (> 90 mmHg) was present in 24.5% of the 
patients, whereas 57.9% had a high SBP (>140 mmHg); 19% of the patients were currently 
treated for high BP. Of the patients with high SBP, 75% received no treatment with anti-
hypertensive medication. Of the patients with a high DBP, 64.1% received no treatment for 
high blood pressure. Of all patients, 71.5% had no WMH, and 44% had a mean MTA score of 
2 or higher. The mean BP in the separate categories of MTA is represented in figure 1. 
 
Figure 1: Mean blood pressure (SBP, DBP and pulse pressure) per MTA score. 
Figure 1: Mean blood pressure per MTA score
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MTA score grouped as follows: 0 = 0-0.5; 1 = 1-1,5; 2 = 2-2,5; 3 = 3,5-4 
 
 
 
The 43 patients with WMH had a median WMH-score of 2 (range 1 to 13). The patients with 
WMH were older (71.3 [SD = 8.0] vs 67.1 [SD = 8.9] years, p = 0.009), had more MTA (p = 
0.002) and were more frequently treated for hypertension (32.6% vs 14%; p = 0.01) compared 
to the patients without WMH. There was no difference in BP between the groups with and 
without WMH. The patients with a presenile onset of dementia had a lower MMSE (19.0 [SD 
= 4.6] vs 21.7 [SD = 5.1], p = 0.004), a lower SBP (141.8 [SD = 20.7] vs 154.4 [SD = 22.3] 
mmHg, p = 0.001), a lower pulse pressure (56 [SD = 14.5] vs 68.3 [SD = 18.0] mmHg, p = 
0.001), less WMH (p = 0.02) and less MTA (p = 0.002) compared to the patients with a senile 
onset of dementia.   
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There was a significant relation between pulse pressure (β = 0.08 [95% CI = 0.00 to 0.15, p = 
0.05] per 10 mmHg pulse pressure,) and (borderline) SBP (β = 0.05 [95% CI = -0.01 to 0.11, 
p = 0.1] per 10 mmHg) and MTA, respectively, whereas this was not found for DBP (table 2). 
Tests for trend revealed a significant relation between SBP and pulse pressure in tertiles and 
the severity of MTA (ptrend=0.05 and ptrend 0.03, respectively). 
 
Table 2: Relation between blood pressure, pulse pressure and medial temporal lobe atrophy. 
 
Multiple linear regression analyses between systolic blood pressure (SBP), diastolic blood pressure (DBP) 
or pulse pressure (PP) and medial temporal lobe atrophy, adjusted for age and sex, for the study population 
as a whole and stratified on the absence or presence of WMH and on the age of onset of dementia. Values 
represent the beta-coefficients per 10 mm Hg blood pressure with 95% confidence intervals. 
a p = 0.01; b p = 0.04; c p = 0.05; d p = 0.006;  e p = 0.03 
 
 
Stratification on WMH revealed a significant association between MTA and SBP (β = 0.12 
[95% CI = 0.03 to 0.21, p = 0.01] per 10 mmHg) and pulse pressure (β = 0.16 [95% CI = 0.05 
to 0.27, p = 0.006] per 10 mmHg), respectively, which was only present in patients with 
WMH, and not in those without (table 2). The interaction between SBP and MTA (p = 0.05) 
and between pulse pressure and MTA (p = 0.05) was significant. Stratification on the age at 
onset showed a significant association between MTA and SBP (β = 0.10 [95% CI = 0.007 to 
0.19, p = 0.04] per 10 mmHg) and pulse pressure (β = 0.10 [95% CI = 0.02 to 0.22, p = 0.03] 
per 10 mmHg) respectively, only in those patients with a senile onset of dementia. This was 
independent from WMH severity. Additional adjustments for MMSE and DM did not alter 
the magnitude of the associations.  
 
Discussion 
We found that pulse pressure and SBP were significantly related to MTA-severity in patients 
with AD, especially in the sub-group with WMH and in those with a senile onset of dementia.  
 Total sample  WMH - WMH +  Presenile Senile 
SBP 0.05 
(-0.01–0.11) 
 
 0.01 
(-0.07-0.09) 
0.12 
(0.03-0.21)a 
 0.01 
(-0.09-0.1) 
0.10 
(0.007-0.19)b 
DBP 0.008 
(-0.11–0.12) 
 
 0.006 
(-0.13-0.14) 
0.07 
(-0.15-0.28) 
 -0.03 
(-0.21-0.14) 
0.02 
(-0.16-0.20) 
PP 0.08 
(0.00-0.15)c 
 0.01 
(-0.09-0.12) 
0.16 
(0.05-0.27)|d 
 0.04 
(-0.1-0.18) 
0.10 
(0.02–0.22)e 
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One of the strong points of our study is the large sample of exclusively mild affected AD 
patients. Furthermore, all patients underwent standardized MRI scanning, and both WMH and 
MTA were rated by a single rater with high intra-observer reliability, with the aid of a visual 
scale that has been shown to have a good correlation with volumetry.26,27 In addition, all 
patients were diagnosed within the same setting by a small group of experienced 
investigators, minimizing diagnostic uncertainty and heterogeneity of the sample.  
However, some methodological issues need to be considered. Our study had a cross-sectional 
design. Therefore a causal relationship between BP, pulse pressure and MTA cannot be 
inferred. However, the dose dependent relation between BP, pulse pressure and MTA 
suggests causality. 
Selection bias may have occurred since the level of BP may be related to the accessibility of 
the outpatient clinic for patients with AD. It may be that those with the highest BP suffer 
more from cardiovascular complications and WMH that prevent them from visiting an 
outpatient clinic, for example due to gait disturbances.32-34 Similarly, it seems plausible that 
patients with the most severe MTA suffer from the most severe dementia, and as a 
consequence are more institutionalized. Such patients may be presumed to visit an outpatient 
memory clinic less often. Consequently, patients with the highest BP and those with the most 
severe MTA might be underrepresented, and therefore may have biased the outcome.  
The degree of MTA was less than one would expect in an AD-sample. AD with a presenile 
onset usually presents with visuo-spatial defects, whereas memory dysfunction occurs later in 
the disease process. Since MTA is thought to be related to memory dysfunction, it could be 
that MTA would occur later in the disease process. In the present sample there is a relative 
large sub-sample of presenile AD patients (41.5%) with a relative high MMSE possibly 
explaining the rather mild degree of MTA. The fact that MTA increases with progression of 
dementia,35-37 and the present sample includes mainly mild demented subjects may explain 
the rather mild MTA in the present sample. 
We only found a relation between SBP and MTA, and not between DBP and MTA. A 
possible explanation may be that DBP is not a good indicator for vascular events in the 
elderly.26,31 This may be due to a decrease in DBP after the age of 50-60,38 especially among 
individuals with atherosclerosis. Our finding of an association between MTA and SBP and 
not with DBP is consistent with this notion. On the other hand SBP has also been shown to 
decrease with aging, and even disproportionably more in patients with dementia, and 
dementia-severity.3,39 Therefore, we included age and MMSE as an indicator of dementia 
severity in our models, but this did not alter the magnitude of the association. 
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The relation between BP and MTA was only present in the patients with a senile onset of AD. 
A possible explanation may be that BP differentially affects the hippocampus in patients with 
senile or presenile AD, or that BP is only related to MTA in senile AD. These data underscore 
the existence of subtypes of AD, among others based on the age of onset and vascular 
comorbidity. This subdivision had already been suggested by Alzheimer himself but is barely 
recognized in current studies.40 
In the present study, the association between SBP, pulse pressure and MTA was most 
outspoken in the subgroup with WMH, suggesting that certain brains are more susceptible to 
vascular factors than others, and that MTA in the absence of WMH has a different pathologic 
substrate, which is probably not vascular.33 A possible mechanism could be that increased BP 
levels cause MTA and WMH by inducing micro vascular changes. However, adjustment for 
the severity of the WMH did not change the magnitude or strength of the association between 
BP and MTA, suggesting that the mechanism of the effect of BP on WMH and MTA is 
different, although both may be a downstream effect of, for example, atherosclerosis.  
Several mechanisms for the relation between BP and MTA have been suggested. Previous 
studies have shown that high BP is related to an increased number of NP and NFT in the 
hippocampus.9,10 Possibly, high BP results in an impaired cerebral blood flow and 
subsequently affects the CA1 area in the hippocampus, which is known to be very sensitive to 
ischemia, resulting in atrophy of the medial temporal lobe.41-43 Another explanation could be 
that a common agent affects both BP and MTA: possible candidates inlude angiotensin 
converting enzym and vasopressin, as well as genetic factors.44,45  
In conclusion, we found that SBP and pulse pressure were associated with MTA in patients 
with AD, especially in those with a senile onset or in those with WMH. Our finding may be 
another step in providing a rationale on how vascular factors could ultimately result in AD. It 
also fuels the notion that treatment of hypertension may be important for the prevention of 
dementia.46 Large prospective studies are needed to unravel the chain of events from elevated 
BP to MTA and the development of AD. 
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Abstract 
Background and purpose 
Medial temporal lobe atrophy (MTA) is a hallmark of Alzheimer’s disease (AD). Its 
progression is often seen during the course of AD, but its frequency and risk factors remain 
unclear.  
 
Methods 
We investigated this in 35 AD patients from whom sequential MRI scans were available. 
White matter hyperintensities (WMH; for the periventricular (PV) and subcortical (SC) region 
separately) and MTA were rated semi-quantitatively.  
 
Results 
In approximately two thirds of all patients progression of MTA was found. The mean MTA 
progression was 0.8 (SD = 0.5) and 0.3 (SD = 0.4) for patients with or without PVWMH at 
baseline (p = 0.01). Patients who showed progression of PVWMH over the course of their 
disease had a significantly higher mean progression of MTA than those without PVWMH 
progression (0.9 (SD = 0.4) and 0.4 (SD = 0.5, p = 0.01). Patients with PVWMH at baseline 
had a 40-fold increased risk for progression of MTA compared to those without baseline 
PVWMH (OR = 40.0, 95% CI = 1.3 to 1.2x103, p = 0.03). Patients with progression of 
PVWMH during the course of the disease had an increased risk for MTA progression (OR = 
3.7 per unit increase of progression of PVWMH, 95% CI = 1.1 to 12.9, p = 0.04). There was 
higher risk for progression of MTA for those with progression of PVWMH than those without 
(OR = 10.9, 95% CI = 1.0 to 122.5, p = 0.05). This was not found for SCWMH.  
 
Conclusions 
Our findings suggest that the presence and the progression of WMH are associated with 
progression of MTA in AD. WMH may be a predictor of the course of the disease and a 
potential treatment target in AD. 
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Introduction 
Medial temporal lobe atrophy (MTA) is one of the first changes seen in the brains of 
Alzheimer’s Disease (AD)1 patients. Its presence has proven to be a sensitive marker for the 
diagnosis of AD and also for future development of AD in patients with mild cognitive 
impairment.2,3 Progression of AD is paralleled by progression of MTA.4 There is very little 
known on factors that influence MTA progression.  
Observational studies show an increased burden of amyloid plaques and neurofibrillary 
tangles by severity of MTA during the course of the AD,1 but prospective follow-up studies 
on the frequency and risk factors for MTA progression in order to assess causality are lacking. 
Identification of potential modifiable risk factors for MTA progression is of importance to 
help advise patients and their relatives on what to expect from the disease in the near future 
and in terms of potential future treatments.   
Potential risk factors for MTA progression include white matter lesions (WMH) in view of a 
recently described relation between WMH and MTA in a cross-sectional study.5 Given that in 
the course of AD WMH also progress over time6 progression of WMH may also be a risk 
factor for progression of MTA. If a causal relation between WMH and MTA progression is to 
be proven MTA progression may be prevented by modifying the progression of WMH by for 
example treatment of the vascular risk factors for WMH such as hypertension. 
We hypothesized that the presence of WMH at baseline and their progression along the course 
of AD are associated with MTA progression. We therefore wanted to investigate the 
frequency distribution of MTA progression among AD patients and the relation between 
baseline and progression of WMH and the progression of MTA in a prospective cohort of AD 
patients. 
 
Methods  
Study population 
We investigated AD patients from a prospective study on AD at the secondary/tertiary referral 
Alzheimer Center of the VU University Medical Centre in Amsterdam who all underwent 
serial MRI scanning. As part of a routine diagnostic procedure all patients underwent a 
standardized work-up involving history taking, physical and neurological examination, blood 
tests (Erythrocyte Sedimentation Rate, haemoglobin, white cell count, serum electrolytes, 
glucose, urea, creatinine, liver function tests, Thyroid Stimulation Hormone and free thyroid 
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hormone, vitamin B1 and B6 levels, lues reactions), Mini Mental State Examination 
(MMSE),7 neuropsychological examination, structural imaging of the brain and a quantitative 
EEG. Final diagnosis was based upon a consensus meeting where all the available clinical 
data and the results of the ancillary investigations were considered. A diagnosis of probable 
AD was based upon the NINCDS-ADRDA criteria.8 All patients provided written informed 
consent for their clinical data being used for research. We identified 35 out of 252 consecutive 
patients with ‘probable’AD who had serial MRI scans available (mean follow-up 2.2 years 
(range: 1.0-5.1 year)). 
 
Magnetic resonance imaging study protocol 
All subject underwent a cranial MRI including coronal T1-weighted and transverse proton 
density (PD) or fluid attenuated inversion recovery (FLAIR) images on a 1.0T scanner 
(Impact, Siemens AG, Germany) using a standardized protocol, including contiguous 3mm 
thick slices for the T1-coronal images and 5 mm thick slices, with an inter-slice gap of 20.0%, 
for the PD and FLAIR images. All sequences yielded an in-plane resolution of 1x1 mm2. The 
second scan was made on the same machine with identical protocol. The images were printed 
as hard copy with a reduction factor of 2.7. 
 
White matter lesions rating scale 
WMH were rated using the Rotterdam Scan Study Rating Scale.9 The rater was blinded to any 
clinical information of the patients. WMH were considered present if these were hyperintense 
on PD or FLAIR images without prominent hypo-intensity on T1 weighted images. WMH 
were assessed according to location in subcortical (SCWMH) and periventricular (PVWMH) 
regions using a previously described protocol.9 In short: the number and size of SCWMH was 
rated on hard copy according to their largest diameter in categories of small (< 3 mm), 
medium (3 to 10 mm) or large lesions (> 10 mm). A total volume of SCWMH was calculated 
by considering them spherical as described previously.9 PVWMH were rated semi-
quantitatively per region: adjacent to frontal horns (frontal capping); adjacent to lateral wall of 
lateral ventricles (bands), and adjacent to occipital horns (occipital capping), on a scale 
ranging from 0 (no white matter lesions), 1 (pencil-thin periventricular lining), 2 (smooth halo 
or thick lining) to 3 (large confluent white matter lesions). The overall degree of PVWMH 
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was calculated by adding up the scores for the three separate regions (range 0-9). Intra-rater 
kappa’s for PVWMH severity grades were between 0.6-0.8. The intra-rater intra-class-
correlation coefficient for SCWMH rating was 0.95. 
 
Medial temporal lobe atrophy 
MTA was rated on a five-point scale (0-4) on a coronal T1 weighted image based on the 
width of the choroid fissure and the temporal horn and the height of the hippocampal 
formation.10 The mean of the left and right MTA score was used in the analysis.  
All MRI scans were rated by an experienced rater with good intra-rater reliability (kappa 
between 0.6 to 0.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coronal slices at the level of the medial temporal lobe at baseline (A); MTA score = 2) and after a follow-up 
period of 3 years (B; MTA score = 4) in a 79 years old male AD patient with progression of MTA. Arrows 
indicate the right MTL.  
 
Other covariates 
Blood pressure was measured manually in a standardised manner by means of a 
sphygmomanometer with the patient in sitting position after 5 minutes of rest based on a 
single measurement. The first and the fourth Korotkoff sounds were used for the systolic and 
diastolic blood pressure, respectively. Hypertension was defined as a baseline systolic blood 
pressure ≥ 140 mm Hg and/or a baseline diastolic blood pressure ≥ 90 mm Hg and/or the 
baseline use of blood pressure lowering medication. Global cognitive function was assessed 
by the mini mental state examination (MMSE).7 
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Statistical analysis 
Progression of both WMH and MTA was defined as an increase of 1 point or more on the 
rating scales between baseline and follow-up. The figure shows a typical example of MTA 
progression. We calculated the mean progression of MTA stratified on absence or presence of 
baseline and of progression of WMH by means of age and gender adjusted ANOVA. Odds 
ratios (OR) were calculated to quantify the association between baseline and progression of 
WMH (independent variable) and progression of MTA (dependent) by means of age and 
gender adjusted logistic regression analysis. Additional adjustments were made for the 
MMSE (as an indicator of dementia severity), systolic and diastolic blood pressure and the 
duration of follow-up. The relation between progression of WMH and progression of MTA 
may be confounded by the severity of baseline WMH since progression of WMH has shown 
to be significantly related to baseline presence of WMH,11 also in patients with AD.6 We 
therefore performed additional adjustments for baseline WMH in all analysis where 
progression of WMH was the independent variable. 
 
Results 
Patients with a follow-up scan were younger than those without (66.2 years (SD = 8.6) vs 
72.3 years (SD = 9.5), p < 0.05). Roughly half of all patients were female, both in the group 
with as well as without a follow-up scan. Mean MMSE at baseline was 21.1 (SD = 5.2). Other 
baseline characteristics are presented in table 1. Except for age and MTA, there were no 
differences in baseline characteristics between those with or without follow-up MRI. 
There were 25 patients (about 70%) who showed MTA progression. Patients < 70 years of 
age had a higher mean progression of MTA than those ≥ 70 years of age (0.7 (SD = 0.5) and 
0.3 (SD = 0.5)), however this was not significant. There was no difference between men and 
women with respect to progression of MTA.  
Progression of MTA was related to the presence of PVWMH at baseline and to progression of 
PVWMH. The mean MTA progression was 0.8 (SD = 0.5) and 0.3 (SD = 0.4) for patients 
with or without PVWMH at baseline (p = 0.01). Patients who showed progression of 
PVWMH over the course of their disease had a significantly higher progression of MTA than 
those without PVWMH progression (0.9 (SD = 0.4) and 0.4 (SD = 0.5), p = 0.01). This was 
not found for SCWMH (table 2). 
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Table 1. Characteristics of the study population at baseline, with or without serial MRI*. 
Characteristic With follow-up Without follow-up p-value 
Number of subjects 35 252  
Age at baseline (years) 66.2 (8.6)  72.3 (9.5) 0.001 
Women (%) 42.9 60.0 0.06 
Mean duration of follow up (years; range) 2.2 (1.0-5.1) n.a.  
Median MTA baseline (range) 1.5 (0-3.5) 2.0 (0-4) 0.048 
Median MTA follow up (range) 2.0 (0-3.5) n.a.  
Median delta MTA (range) 0.5 (-0.5-1.5) n.a.  
Median PVWMH baseline (range) 1.0 (0-6) 1.0 (0-9) 0.98 
Median PVWMH follow up (range) 2.0 (0-6) n.a.  
Median delta PVWMH (range) 0.0 (0-3) n.a.  
Median volume (ml.) SCWMH baseline (range) 0.04 (0-3.2) 0.03 (0-3.9) 0.70 
Median volume (ml.) SCWMH follow up (range) 0.06 (0-3.9) n.a.  
Median volume (ml.) delta SCWMH (range) 0.01 (-0.3 – 0.9) n.a.  
Hypertension (%) 84.7 79.0 0.43 
Systolic blood pressure (mm Hg) 151.9 (23.8) 152.1 (23.3) 0.92 
Diastolic blood pressure (mm Hg) 84.1 (10.6) 85.7 (10.7) 0.34 
MMSE 21.1 (5.2) 19.9 (5.4)  0.21 
* Values are age and gender adjusted means (SD) or percentages. n.a.: not applicable. 
 
Table 2. Mean progression of MTA by baseline and progression of WMH*. 
 Baseline PVWMH Progression PVWMH 
 absent present absent Present 
Mean MTA progression 0.3 (0.4)  
n = 17 
0.8 (0.5)† 
n = 18 
0.4 (0.5) 
n = 9 
0.9 (0.4)† 
N = 26 
     
 Baseline SCWMH Progression SCWMH 
 absent present absent Present 
Mean MTA progression 0.6 (0.5) 
 n = 8 
0.5 (0.5) 
n = 27 
0.3 (0.4) 
n = 11 
0.5 (0.4) 
N = 24 
* Means are adjusted for age, gender, duration of follow up and blood pressure; † p = 0.01 
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Patients with PVWMH at baseline had a 40-fold increased risk for progression of MTA 
compared to those without baseline PVWMH (OR = 40.0, 95% CI = 1.3 to 1.2x103, p = 0.03). 
Patients with progression of PVWMH during the course of the disease had an increased risk 
for MTA progression (OR = 3.7 per degree increase of progression of PVWMH, 95% CI = 
1.1 to 12.9; p = 0.04). There was higher risk for progression of MTA for those with 
progression of PVWMH than those without (OR = 10.9, 95% CI = 1.0 to 122.5, p = 0.05). 
This was not found for SCWMH (table 3). 
Adjustment for confounding factors, including the degree of baseline WMH, did not alter the 
magnitude of the association. 
 
Table 3. The relative risk for MTA progression in AD patients by baseline and progression of 
white matter lesions (OR and 95% confidence intervals). 
 Periventricular WMH Subcortical WMH 
 baseline* progression† Baseline* progression† 
Risk for progression of MTA 40.0 (1.3-1.2x103)‡ 3.7 (1.1-12.9)¶  0.7 (0.1-5.2) 1.0 (0.99-1.02) 
Adjustments were made for age, gender, duration of follow-up, systolic and diastolic blood pressure. 
* The reference group consists of patients without WMH at baseline. † per unit of WMH progression. 
‡ p = 0.03; ¶ p = 0.04 
 
 
Discussion 
We found that patients with WMH at baseline and those with an increase of WMH, especially 
the PVWMH, over a mean two-year period of follow-up had a significantly higher risk for 
progression of MTA. 
Strengths of our study are the prospective nature of the study and the fact that baseline and 
follow-up scans were rated independently from each other with high intra-rater agreement.  
Some methodological issues need attention. Selection bias may have influenced our findings 
in several ways. Due to the nature of a follow-up study only those participants that were still 
alive at follow-up, undergo serial MRI scanning. Therefore it could be that selective survival 
of people with a relatively mild degree of WMH at baseline and those with a relatively mild 
progression of WMH has occurred since severity of WMH is related to mortality.12 Another 
form of selection bias may be the underrepresentation of those patients who are in a more 
advanced stage of the disease, and presumably have the highest degree of WMH, since those 
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patients are not very likely to show up at regular outpatient-clinic controls and at repeated 
MRI examination, for example due to mobility related problems.13 However we do not think 
that these forms of bias significantly influenced our findings since in a previous study we 
found a linear relation between the degree of WMH and MTA, consequently those with the 
most severe WMH would most likely to have the most severe MTA. 
WMH and MTA were rated with the Rotterdam scan study scale9 and with a semi quantitative 
MTA rating scale respectively,10 which both were not developed for the detection of change 
in a longitudinal design. The use of the Rotterdam scan study scale for this purpose proved to 
be poor in a recent validation study,14 especially for the detection of change of PVWMH but 
performed better for the detection of change of SCWMH. A reason for this could be the so-
called ceiling effect that presumably does not apply to the SCWMH. PVWMH that were 
already rated in the highest category at baseline (and which are most likely to progress) 
cannot contribute to progression on these scales since they are already in the highest category, 
whereas SCWMH were counted taking into account number and size of lesions without a 
predefined maximum, thus avoiding a ceiling effect. However the presumed influence of this 
ceiling effect is limited in our study since patients in our study had a median baseline 
PVWMH of 1.0 (which is way below the maximum of 9.0) compared to 6.0 in the study of 
Prins et al.14  
This type of validation study has never been done for the detection of MTA change over time 
with the semi quantitative MTA rating scale we used but similar reasoning may apply, since 
mean MTA scores in our study were quite low and far below the maximum of the score.  
Our finding of a relation between progression of WMH and progression of MTA could be 
confounded by baseline WMH since this has proven to be related to progression of WMH.6,11 
However, adjustment for baseline WMH did not alter the magnitude of the association 
rendering this explanation unlikely. 
Our study does not provide an explanation on how WMH may ultimately lead to MTA in AD. 
An explanation could be that the medial temporal lobe is disconnected from connected 
cortical areas by the vascular WMH in the white matter tracts subserving the cortical 
association areas15,16 leading to shrinkage of the medial temporal lobe due to Wallerian 
degeneration. Despite the fact that ours is a prospective study, both WMH and MTA were 
already present at baseline examination therefore causal inference on the underlying 
mechanism cannot be made from our study. It is not known why periventricular and 
subcortical WMH would have a differential influence on MTA. An explanation could be that 
the periventricular WMH affect areas of long fiber tracts that connect several distant cortical 
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areas with each other (including the MTA)15,16 whereas subcortical WMH mainly disrupt 
short loops of cortico-cortical connections not related to distant structures such as the MTA.17 
Still, a remaining explanation for our finding includes the possibility of an identical 
underlying mechanism for both WMH and MTA such as changes in the amyloid metabolism 
or vascular brain disease. The predominant pathology in MTA even early in the course of AD 
is the presence of amyloid
 β1-42 in amyloid plaques.18 Whereas recent studies also indicated a 
relation between the level of circulation Aβ1-42 and the presence of WMH.19 Consequently, by 
these mechanisms progression of amyloid deposition could both lead to progression of both 
WMH and MTA, thereby explaining our finding. Another underlying mechanism may be that 
cerebral ischemia not only results in WMH but also in MTA. Indeed, pathological studies 
found micro-infarcts in the medial temporal lobe in patients with AD.20 
Our findings suggest a relation between both baseline and progression of WMH and 
progression of MTA. When our findings are substantiated this may indicate that the presence 
of PVWMH on an MRI scan can be used as a tool that is able to predict MTA progression 
(and as such presumably progression of the disease) in still relatively mildly demented 
patients years before end stages of the disease. As such they may function as a surrogate end 
point in clinical trials that aim at modifying the course of AD.21 If a causal relation between 
WMH and MTA progression is to be proven MTA progression may be prevented by 
modifying the progression of WMH by for example treatment of the vascular risk factors for 
WMH such as hypertension.22 
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Abstract 
Background 
Type 2 Diabetes Mellitus (DM2) leads to cognitive impairment and dementia, which may 
reflect microvascular and macrovascular complications as well as neurodegenerative 
processes. There are few studies of the anatomical basis for loss of cognitive function in 
DM2. 
 
Aim 
To investigate the association between DM2 and markers of brain aging on magnetic 
resonance images (MRI), including infarcts, lacunes and white matter hyperintensities 
(WMH), as markers of vascular damage, and general and hippocampal atrophy (HA) as 
markers of neurodegeneration.  
 
Setting 
The Honolulu Asia Aging Study of Japanese American men born between 1900-1919 and 
followed since 1965. 
 
Methods 
Prevalent and incident dementia was assessed. Associations between MRI markers and 
diabetic status were estimated with logistic regression, controlling for socio-demographic and 
other vascular factors. 
 
Results 
The prevalence of DM2 in the cohort is 38%. Subjects with DM2 had a moderately elevated 
risk for lacunes (OR = 1.6, 95% CI = 1.0 - 2.6) and HA (OR = 1.7, 95% CI = 0.9 - 2.9). The 
risk for both HA and lacunes/infarcts was twice as high in subjects with, compared to those 
without DM2. Among the group with DM2, those with the longest duration, taking insulin, 
and with complications had relatively more pathologic brain changes. 
 
Conclusions 
There is evidence that older persons with DM2 have an elevated risk for vascular brain 
damage and neurodegeneration. These pathologies may be the anatomical basis for increased 
risk for cognitive impairment or dementia in DM2.  
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Introduction 
Subjects with Type 2 Diabetes Mellitus (DM2) are at increased risk for cerebral 
complications, including stroke,1,2 cognitive impairment3,4 and dementia.5-7 This may partially 
reflect the systemic microvascular (retinopathy, nephropathy, neuropathy)8 and macrovascular 
(coronary heart disease, peripheral arterial disease)9-11 complications that characterize DM2. 
Characteristics of subjects with DM2, such as hyperglycemia, elevated blood pressure, 
hyperinsulinemia and dyslipidemia, may also directly affect neuronal viability. In DM2, the 
phosphorylation of tau may be enhanced,12 the breakdown of amyloid might be 
diminished,13,14 and advanced glycated end products may contribute to the formation of 
neurofibrillary tangles (NFT) and neuritic plaques (NP),15 which are markers of Alzheimer’s 
disease (AD), a major neurodegenerative disease in the elderly. Autopsy data based on the 
Honolulu Asia Aging Study (HAAS) cohort show a significant association of DM2 to infarcts 
as well as hippocampal NFT and NP.6  
Taken together, the evidence suggests that DM2 may contribute to cognitive disorders not 
only via vascular lesions, but also via neurodegeneration. To test this hypothesis, we 
investigated the association between DM2 and magnetic resonance image [MRI] findings of 
infarcts, lacunes and white matter hyperintensities (WMH), as markers of vascular damage, 
and general and hippocampal atrophy (HA)16 as markers of neurodegeneration. Data are from 
the population-based Honolulu Asia Aging Study (HAAS).  
 
Methods 
The design of the HAAS has been described elsewhere.17 Briefly, the cohort consisted of 
Japanese-American men born between 1900 and 1919, living on the Island of Oahu, Hawaii, 
who were enrolled in 1965 as a part of the Honolulu Heart Program (HHP). After the first 
exam (1965-1968), the men were re-examined in 1968 through 1970 (exam 2) and 1971 
through 1974 (exam 3). In 1991 to 1993, the HAAS was established with the aim of 
investigating neurodegenerative diseases in the cohort. Of the survivors 3734 men (80% 
response) underwent a complete examination (exam 4). The cohort was re-examined 1994 to 
1996 (exam 5), with an 84% participation rate among those with a previous cognitive screen. 
At each exam, clinical measures were made and socio-demographic and medical conditions 
assessed. At exam 4 and 5, cognitive status was tested and prevalent (exam 4) and incident 
(exam 5) dementia cases were identified. The Kuakini Medical Center Institutional Review 
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Board approved this study. All respondents signed informed consent forms, except those who 
were demented. In that case an informed caretaker signed the consent. 
 
MRI sub-study 
Sample 
In exam 5, a MRI study was conducted on a sub-sample of the cohort selected on the basis of 
information from both exams 4 and 5.18 The sample included a ~10% random sample of exam 
5 participants, and a randomly selected over-sample of those with prevalent dementia 
(excluding the severely demented, who might not be able to undergo the procedure), those 
who scored poorly on the Cognitive Abilities Screening Instrument19 but did not meet criteria 
for dementia, those with apolipoprotein E ε4 genotype, and those with clinical stroke. 
Dementia was ascertained in a multi-step procedure, described in detail elsewhere.17 
Diagnosis was made in a consensus conference: DSM-IIIR criteria20 were applied for 
dementia, NINDS-ADRDA21 for AD, and the CADDTC for vascular dementia (VaD).22 
Stroke was identified from the first exam through to the MRI exam as a part of the ongoing 
HHP hospital surveillance system that uses multiple sources of information to complete a 
consensus diagnosis. Apolipoprotein E genotyping based on samples collected at exam 4 was 
performed with restriction isotyping using a polymerase chain reaction.23 
Of the 845 men invited for the procedure, 621 MRI scans were acquired, and 543 MRI scans 
could be processed successfully for all relevant data. Non-participation was due to death, 
refusal and technical problems. Compared to the 302 subjects not included in the analyses, the 
included subjects had the same prevalence of DM2, hypertension and stroke, but had more 
frequently the apolipoprotein E ε4 allele (36 vs 29%, p = 0.04) and had more years of 
education (p = 0.01).   
 
Imaging protocol 
 Scans were acquired with a GE Signa Advantage, 1.5 Tesla machine at Kuakini Medical 
Center, Honolulu. The acquisition protocol typically required 20 minutes and included four 
pulse sequences: sagital, 24 cm FOV, TR = 5000, TE = minimum, 5 mm contiguous 
interleaved sections, 192 views, 1 repetition; 3D coronal spoiled gradient echo sequence 
(SPGR), 22 cm FOV, minimum TR and TE, 1.6 mm slice thickness, 124 slices, 1 repetition, 
45 degree flip angle; axial proton density weighted fast-spin echo sequence, 3 mm interleaved 
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sections, minimum TE, TR = 2300 msec, 24 cm FOV, 256 views, 1 repetition, 4 echo train 
length, minimum inter-echo spacing; another axial fast-spin echo sequence, T2-weighted, 3 
mm interleaved sections, TR 4000 msec or more, 24 cm FOV, 256 views, 1 repetition, echo 
train length equal to 8, minimum inter-echo spacing.  
 
MRI-readings 
WMH, infarcts and lacunes: Semi-quantitative readings based on a protocol developed for the 
Cardiovascular Health Study were performed at the Johns Hopkins Neuroradiology Reading 
Centre by readers blinded to subject risk factors and health. Scans were evaluated for the 
number of lacunes and infarcts as defined by Longstreth.24 In short, infarct or lacune are 
defined as a lesion at least 3 mm in diameter, visible on both the T1-weighted images and the 
PD/T2-weighted images and approach CSF-density. Infarcts in the cortical gray matter and 
basal ganglia may only be CSF-like on the T2/PD images. Lacunes are defined as exclusively 
located subcortically (including the basal ganglia) and are between 3 and 20 mm in all 
dimensions. Infarcts are larger than 20 mm or located cortically. WMH appear isointense 
compared to the white matter on the T1-weighted images and hyperintense on the axial PD-
weighted images. They are rated on a 10-point scale that ranges from no white matter signal 
abnormalities to all white matter involved.25 
Atrophy: The inner table distance and the bifrontal distance (largest diameter between the left 
and right frontal horn of the lateral ventricles) were measured on the most superior T1-
weighted axial image where the lateral ventricles were indented by the thalami. The central 
sulcus width was the largest perpendicular diameter of the right central sulcus, also measured 
on the T1-weighted axial sequence. As a measure of cortical volume, the central sulcus width 
was divided by the inner table distance; cortical atrophy was defined as the highest quartile of 
this measure. As a measure of subcortical volume, the bifrontal distance was divided by the 
inner table distance; subcortical atrophy was defined as the lowest quartile of this measure. 
General atrophy was defined as the presence of cortical and/or subcortical atrophy. 
Hippocampus volume:  The coronal SPGR sequence was reformatted to oblique coronal, 
perpendicular to the long axis of the left hippocampus. Using MEDx version 3.41 software 
(Sensor Systems, Inc. Sterling, VA), one rater, blind to subjects characteristics, measured the 
left and right hippocampi as described in an earlier report.26 The hippocampal formation, 
including the subiculum, dentate gyrus, cornu ammonis, fimbria and alveus, was measured in 
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its total length from anterior until the crux of the fornix was seen. The intra-class correlation 
coefficient for the intra-reader agreement was 0.97.  
Hippocampal volumes were corrected for head size, estimated on the axial proton density 
sequence, by measuring the intra-dural area (total intracranial volume (TICV)). For each 
subject hippocampal volume was multiplied with the mean TICV of the sample and divided 
by the TICV of the subject.26  
 
Assessment of DM2 
DM2 was assessed at the fourth exam. Subjects with a self-reported doctor’s diagnose of 
DM2, use of oral hypoglycaemic medications or insulin are classified as DM2. To identify 
other individuals with glucose dysregulation, we obtained fasting and 2-hr glucose levels on 
those who were not known to have DM2, and did not have a gastrectomy, active peptic ulcer, 
or stomach cancer, by administering a 75g-glucose drink.27 Based on the recommendations of 
the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus28 individuals 
with fasting blood glucose > 126 mg/dl (> 7.0 mmol/l) or a 2-h post load glucose > 200 mg/dl 
(> 11.1 mmol/l) were classified as having DM2; individuals with a fasting glucose between 
5.1 and 7.0 mmol/l or a 2-hour post load glucose between 7.8 and 11.1 mmol/l were classified 
as glucose intolerant (IGT); subjects with a fasting glucose < 5.1 mmol/l and a 2-hour post 
load glucose < 7.8 mmol/l were classified as normoglycemic (NG). Subjects reporting DM 
(not those newly detected by the study) were asked the duration of their disease, and whether 
they suffered from complications of DM2, including amputation, retinopathy, nephropathy, or 
peripheral neuropathy. 
 
Measures of confounding or mediating variables 
We considered the following factors to be possible confounders or mediators of the 
association between DM2 and MRI-measurements: age, education (years), history of coronary 
heart disease (CHD), ankle-brachial index (ABI), mid-life smoking (never (reference), current 
and past), systolic blood pressure (SBP), body mass index (BMI) and total cholesterol, as well 
as treatment with anti-hypertensive medication. CHD history was assessed at baseline in 1965 
and throughout the entire follow-up to the MRI exam. ABI was measured at exam 4. Smoking 
was collected by questionnaire at the mid-life exams (exam 1, 2 and 3). The values of BMI 
(kg/m2), total cholesterol (mg/dl) and SBP (mmHg) are the average of these factors measured 
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at the three mid-life exams Treatment with anti-hypertensive medication was based on self-
report (exam 1-3) or by presentation of medication vials (exam 4).  
 
Statistical analyses 
Age-adjusted differences in subject characteristics were examined across diabetic subgroups 
using analyses of variance if the characteristic was continuously distributed and with Mantel-
Haenszel test if it was categorical.  
Logistic regression was used to estimate the association of the three glycemic categories 
(DM2, IGT and NG) to brain outcomes. For the analyses we defined the brain outcomes as 
follows: lacunes (present/absent), infarcts (present/absent), substantial WMH (score 4 and 
higher versus the rest), severe HA (the lowest 25th percentile of hippocampal volume versus 
the rest) and general atrophy. To examine the simultaneous risk for both vascular damage and 
HA, we created a polytomous four-level outcome: only HA, only infarcts or lacunes; both HA 
and lacunes/infarcts. The reference group had no infarcts, lacunes or HA.  
Three models were estimated: model 1, adjusted for age and education; model 2 also adjusted 
for MRI variables other than the lesion of interest; and model 3 adjusted for apolipoprotein E 
genotype, dementia status, smoking, alcohol use, history of CHD and stroke, SBP, anti-
hypertensive drug use, cholesterol, BMI and ABI. We also conducted sub-analyses to 
investigate whether subjects with presumably more severe or long-standing DM2 were at 
higher risk for the MRI outcomes. Markers of disease history included whether insulin is 
used, duration of disease and self reported presence of DM-related amputation, eye, kidney or 
peripheral neuropathic complications. Analyses were conducted with the Statistical Analysis 
System [v. 8]; the analyses with the polytomous outcome were conducted with STATA.29  
 
 
Results 
 
In the sample, 38% had DM2 (65% of whom had known diabetes), 25% had IGT and 37% 
were NG (table 1). The mean age of the men was 81.6 years (SD = 5.0). Proportionately more 
subjects with DM2 used anti-hypertensive drugs, had CHD, smaller hippocampi, and more 
lacunes (p < 0.05, age adjusted). Insulin levels, and by definition, fasting glucose levels were 
higher in subjects with DM2 or IGT (p < 0.001 and p < 0.05, respectively) compared to NG.  
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Table 1: Characteristics of the MRI sample by diabetes status: the HAAS 
Variable No diabetes IGT DM2 
N 204 137 202 
Age (years (SD)) 81.3 (4.9) 81.8 (5.0) 81.7 (5.1) 
Education (years (SD)) 10.2 (3.3) 10.4 (2.8) 10.3 (3.2) 
SBP (mmHg (SD)) 131 (16) 133 (18) 134 (17) 
DBP (mmHg (SD)) 83 (9) 83 (9) 83 (10) 
BMI (kg/m2 (SD)) 23.5 (2.7) 23.5 (2.2) 24.3 (2.7) 
Antihypertensives (%) *  41 47 55  
Total cholesterol (mg/dl (SD)) 215 (31) 220 (30) 222 (32) 
Fasting glucose (mg/dl (SD)) †  98 (6) 107 (8) 132 (37) 
Fasting insulin (µIU/ml (SD))* 12.6 (9.3) 14.0 (7.4) 18.6 (15.8) 
Smoking (%)    
Former 34.3 31.4 55 
Current 25.0 19.0 2.5 
Apo E  ε4 (%) 36.8 38.0 35.1 
ABI (SD) 1.04 (0.15) 1.04 (0.15) 1.03 (0.19) 
CHD (%)* 12.3 10.2 18.3 
Stroke (%) 6.9 11.7 9.4 
 Dementia (%) 21 20 22 
AD 9.8 8.8 8.9 
AD w/ CVD 2.5 5.1 5.4 
VaD 2.9 3.6 5.4 
Hippocampal volume (mm3 (SD)) * 5406 (856) 5430 (855) 5348 (805) 
Hippocampal atrophy (%) 22 23 27 
Lacunes (%)*    
0 61.8 61.3 47.5 
1 19.6 16.1 24.8 
>2 18.6 22.6 27.8 
White Mater Hyperintensities (%)    
0-3 73.5 69.3 74.8 
4-9 26.5 30.7 25.2 
Infarcts (%) 9.8 13.0 13.4 
General atrophy (%)  41.1  41.6 46.0 
p-values adjusted for age. *p<0.05; †p<0.001. Smoking: 30 missing subjects.  
Apo E ε4 groups includes 15 subjects with ε 24. 
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Table 2: Association between diabetes mellitus and MRI-outcome variables: the HAAS. 
  
 Model 1 Model 2 Model 3 
General atrophy    
NG 1 1 1 
IGT 1 
(0.6-1.5) 
 
1 
(0.6-1.5) 
1 
(0.6-1.6) 
DM2 1.2 
(0.8-1.8) 
1.2 
(0.8-1.7) 
1.1 
(0.7-1.7) 
WMH    
NG 1 1 1 
IGT 1.2 
(0.7-1.9) 
 
1.2 
(0.7-1.9) 
1.3 
(0.8-2.3) 
DM2 0.9 
(0.6-1.4) 
0.9 
(0.6-1.4) 
1.1 
(0.7-1.9) 
Infarcts    
NG 1 1 1 
IGT  1.4 
(0.7-2.9) 
 
1.6 
(0.8-3.1) 
1.0 
(0.4-2.7) 
DM2 1.5 
(0.8-2.7) 
1.5 
(0.8-2.8) 
1.9 
(0.8-4.3) 
Lacunes    
NG 1 1 1 
IGT 1.0 
(0.6-1.6) 
 
1.0 
(0.6-1.6) 
0.9 
(0.6-1.6) 
DM2 1.8 
(1.2-2.6) 
1.8 
(1.2-2.6) 
1.6 
(1.0-2.6) 
Hippocampal atrophy    
NG 1 1 1 
IGT 1.0 
(0.6-1.8) 
 
1.0 
(0.6-1.7) 
1.2 
(0.7-2.3) 
DM2 1.3 
(0.8-2) 
1.3 
(0.8-2.1) 
1.7 
(0.9-2.9) 
Model 1: adjusting for age and education. 
Model 2: as model 1, for atrophy and hippocampal atrophy also adjusting for WMH, infarcts 
and lacunes; for WMH, infarcts and lacunes also adjusting for general atrophy.  
Model 3: as model 1, also adjusting for Apo E genotype, dementia, smoking, alcohol, CHD, 
ABI, systolic blood pressure, blood pressure treatment, BMI, total cholesterol and stroke.  
General atrophy = cortical atrophy (the highest quartile of the width of central sulcus/ inner 
table distance) and/or subcortical atrophy (the lowest quartile of the bifrontal distance/ inner 
table distance); WMH = wml score > 4; infarcts = cortical infarcts (any cortical infarcts) and/or 
subcortical infarcts (any subcortical infarcts); lacunes = any lacunes; hippocampal atrophy = 
lowest quartile of the hippocampal volumes.  
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Compared to NG men, those with DM2 had a raised risk for lacunes (OR = 1.6, 95% CI = 
1.0- 2.6) (table 2). Subjects with DM2 similar risk for general atrophy as did the NG group. In 
the fully adjusted model 3, the risk for HA was moderately higher for DM2 subjects 
compared to NG subjects (OR = 1.7, 95% CI = 0.9- 2.9). Subjects with IGT had essentially 
the same risk as the NG subjects for all investigated MRI outcomes (table 2). 
The combined groups based on presence or absence of vascular lesions and HA (table 3) 
suggest that those with DM2 have an two times increased risk for a mixed pathology of 
vascular lesions and HA. However, the risk in the mixed profile group is similar to what 
would be expected if DM2 increased the risk for the two types of pathology in an additive 
manner. Compared to the NG, the IGT did not have a significantly higher risk for these 
outcomes.  
 
Table 3: Association of diabetes mellitus, hippocampus and lacunes/infarcts: the HAAS 
 
 Model 1 Model 3 
Hippocampal atrophy only   
IGT 1.4 (0.7-2.7) 1.5 (0.7-3.1) 
DM 1.5 (0.8-2.7) 1.7 (0.8-3.4) 
Lacunes/infarcts only   
IGT 1.2 (0.7-2.0) 1.2 (0.7-2.1) 
DM 1.9 (1.2-3.0) 1.8 (1.1-2.9) 
Hippocampal atrophy and 
lacunes/infarcts 
  
IGT 0.9 (0.0.4-2.0) 0.9 (0.4-2.30 
DM 2.1 (1.1-4.11) 2.0 (0.9-4.4) 
 
Model 1: adjusting for age and education 
Model 3: as model 1, also adjusting for Apo E genotype, dementia, smoking, CHD, ABI, systolic blood 
pressure, blood pressure treatment and BMI. 
Hippocampal atrophy = lowest quartile of the hippocampal volumes without lacunes or infarcts; 
lacunes/infarcts = any lacunes or infarcts without hippocampal atrophy; hippocampal atrophy and 
lacunes/infarcts = lowest quartile of the hippocampal volumes with lacunes or infarcts. 
 
 
Only 10 subjects with DM2 (5% of DM2) used insulin. The mean hippocampal volume of 
these subjects was smaller than those subjects with DM2 who did not take any medications 
(4778 mm3 (SD 825) vs 5400 (SD 833) mm3 respectively), they had more frequently general 
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atrophy (70% vs 42.7%); 40% had hippocampal volumes in the lowest quartile, and 50% had 
lacunes. Three of the ten were demented. There were 49 subjects with DM2 (24.2%) who 
used oral hypoglycaemic drugs. The average hippocampal volume of these subjects was 5312 
(SD 818) mm3, 29% had small hippocampi, 59 % had lacunes and 9 were demented.  
Twelve subjects reported DM2-related complications. Compared to subjects with DM2 
without, those with complications had slightly more brain atrophy (59% vs 50%) and infarcts 
(25% vs 10%), but the sample is very small. Compared to the subjects with DM2 ≤ 5 years (n 
= 53), those with DM2 for more than 20 years (n = 25) had more lacunes (68% v 54.7%), 
hippocampal atrophy (44% vs 28.3%), infarcts (20% vs 15%), and WMH (36% vs 20.7%).  
 
Discussion 
Subjects with DM2 had an elevated risk for lacunar infarction, and a borderline significantly 
raised risk for HA. The risk for both infarcts and HA was twice as high in the subjects with 
DM2 compared to subjects without DM2 after adjusting for other vascular factors. This risk 
estimate suggests there is no synergism between the two pathologies. Compared to NG, 
subjects with IGT, who are at high risk of developing DM2, had no elevated risk for general 
atrophy, lacunes, infarcts or HA. These associations were independent of other vascular 
outcome measures and risk factors, and also independent of each other. 
This study had several strengths. It is based on a large sample of subjects with MRI of the 
brain, and cardiovascular data that were collected prospectively from mid-life up through late-
life when the MRI was acquired. Also, we separated the subjects with IGT, who are at risk for 
DM2, from the subjects with IGT and DM2, so groups with different degrees of glucose 
regulation could be compared. The finding of very small hippocampi in insulin users, and 
proportionately more brain pathology in those who have been DM2 at least 20 years, suggest 
that the amount of brain pathology may increase with disease severity or duration. However 
this needs to be further investigated in a larger sample that is prospectively followed. 
When generalizing the results to other reports, some characteristics of the sample should be 
noted. It has been reported that the prevalence of DM2 and glucose dysregulation in this 
cohort is comparatively high, and that this may reflect differences in the relative contributions 
to the disease of insulin resistance, glucose over-production, degree of impaired ß-cell 
function, and genetics.30 Such differences may also account for the relatively low use of 
insulin and complications in this diabetic population. Other differences that might modify 
these results include the fact these men are relatively lean, and the mean age in the cohort is 
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high [>80 yrs]. It is likely that many subjects with DM2, who have severe complications of 
the disease, do not reach this age. If mortality is selective for men at risk for DM2 and 
cerebrovascular changes, this would change the estimates of the associations reported here. In 
this context, the risk estimates we found are of moderate size. It should also be noted that the 
MRI sample is not a random sample of the cohort but a sample selected based on certain 
characteristics including dementia, poor cognitive performance, stroke and Apolipoprotein E 
genotype.   
DM2 leads to both microvascular and macrovascular changes. Atherosclerosis of the large 
extra- and intracranial vessels, decreased cerebral blood flow, impaired cerebrovascular 
reactivity, thickening of the capillary basement membrane and endothelial cell degeneration 
of microvessels are all described in DM2 (for review, see 31). We found associations between 
DM2 and lacunes, which is a marker for microvascular or small vessel disease. In another 
community-based study, subjects with DM2 also had a higher risk for lacunes compared to 
NG.25 A study with serial MRI-scans also detected more new lacunes in the subjects with 
DM2.32 The idea that DM2 leads to small vessel disease in the brain is supported by these 
studies. However, WMH is also considered to be small vessel disease but we did not find an 
association between those lesions and DM2. This might be due to the scoring system that was 
used. Although, as expected, the score is significantly associated with age, clinically silent 
stroke, higher systolic blood pressure and impaired cognition,33 it does not evaluate the 
distribution of the lesions, or provide a quantitative measure of lesion load. Further, we did 
not acquire a fluid attenuated inversion recovery sequence, so WMH may have been 
missed.34-36 However, the lack of association between DM2 and WMH has also been reported 
in other studies,37,38 in which a semi-quantitative method for estimating the WMH volume has 
been used. These findings suggest that, in DM2, WMH may have a different pathologic basis 
than lacunes, but this needs to be further investigated.  
Cortical and subcortical infarcts are caused by macrovascular or large vessel disease. We did 
not find a significant association between DM2 and infarcts, although risk ratios were raised. 
This is consistent with reports from other studies.37,38 This is a notable finding, as DM2 is a 
risk-factor for stroke.2,39 The difference may be related to selective mortality of subjects with 
DM2 at risk for macro-vascular disease.  
Hippocampal atrophy is a general marker for neurodegenerative processes, particularly in 
AD.16 Cerebral hypoxia-ischemic conditions can also lead to cell death and ensuing 
hippocampal atrophy.26,37 Subjects with DM2 are also at moderately increased risk for HA, 
particularly when infarcts and lacunes are also present. Adjusting for vascular risk factors 
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(model 3) slightly attenuated the odds ratio, suggesting some mediation by these factors. This 
is consistent with the findings in the HAAS autopsy study, which showed both amyloid 
related pathology and vascular pathology were more frequent in DM2 compared to the rest of 
the sample.6 In the present study, DM2 was not associated with general atrophy. The large 
community-based study CASCADE did find that DM2 was associated with an increased risk 
for cortical atrophy,38 particularly in those with hypertension. These subjects were much 
younger than those in the HAAS.  
There are several mechanisms that can explain the influence of DM2 on neurodegeneration. 
Insulin has an inhibitive effect on the phosphorylation of tau. Tau is a phosphoprotein of the 
brain, and normally has 2 or 3 phosphate groups. Hyperphosphorylation of tau can lead to 
NFT, what is a characteristic of AD. As DM2 is characterized by signalling defects in insulin 
the inhibitive effect of insulin on phosphorylation of tau12 may be diminished. Dysfunction of 
the insulin degrading enzyme (IDE) may also be a possible pathologic link between AD and 
DM2. This enzyme is known to degrade insulin and β-amyloid. In DM2, dysfunction of IDE 
causes high levels of insulin and β-amyloid. Deposition of β-amyloid into NP is characteristic 
of AD. In AD, hyperinsulinemia is more prevalent compared to controls, and the activity and 
amount of IDE is diminished.40,41 Interestingly, chromosome 10 contains the genes for IDE, 
and potentially genes for both late onset AD and DM2.13,14,42 Another possible 
neurodegenerative mechanism is through the neurotoxic advanced glycation end products, 
caused by hyperglycemia, which may contribute to the formation of NFT and NP.15,43  
We did not find an increased risk for MRI detected brain changes in men who had IGT. There 
are data based on 30 subjects without DM244 suggesting that fasting and 2-hour glucose levels 
were negatively associated with hippocampal volume. However, studies based on larger, less 
selected samples, are contradictory regarding the risk for cognitive impairment in those with 
IGT.45,46 Given the high prevalence of IGT it will be important to further investigate this 
group in studies of brain aging. 
In summary, we found that subjects with DM2 had a moderately elevated risk for vascular 
brain damage, such as lacunes, and for neurodegeneration, such as is indicated by HA. Due to 
advances in treatment, subjects with DM2 are living longer. However, the pathology may 
cause cognitive impairment and subsequent difficulties in disease management. Further 
studies on the changes in brain structure and correlation with cognition in DM2 are warranted. 
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Abstract 
Hypothesis 
Based on recent findings on the association between vascular risk factors and hippocampal 
atrophy, we hypothesized that hypertension and diabetes mellitus (DM) are associated with 
medial temporal lobe atrophy (MTA) in a sample with non-disabled subjects, independent of 
the severity of white matter hyperintensities (WMH).  
 
Methods 
In the Leukoaraiosis And DISability in the elderly (LADIS) study, we investigated the 
relation between DM, hypertension, blood pressure and MTA in 582 subjects, stratified by 
WMH severity, using multinomial logistic regression. MTA was visually scored for the left 
and right medial temporal lobe (score 0 to 4), and averaged.  
 
Results 
Mean age was 73.5 year (SD 5.1), 54% was female. Of the subjects, 15% had DM, and 70% 
had a history of hypertension. Subjects with DM had a significantly raised odds for MTA 
score 3 (OR = 2.9; 95% CI = 1.1 – 7.8), and a modestly increased odds for MTA score 2 (OR 
= 1.8; CI = 0.9 – 4) compared to a MTA score of 0 (no atrophy). Systolic and diastolic blood 
pressure and a history of hypertension were not associated with MTA. There was no 
interaction between DM and hypertension. Stratification on WMH did not alter the 
associations.  
 
Conclusion 
Our study strengthens the observation that MTA is associated with DM, which is independent 
of the amount of small vessel disease as reflected by WMH. 
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Introduction 
Structures in the medial temporal lobe have a crucial role in memory function. Medial 
temporal lobe atrophy (MTA) is classically thought to be a result of neurodegeneration with 
deposition of neurofibrillary tangles and neuritic plaques,1,2 especially in Alzheimer’s disease 
(AD). However, new findings from two longitudinal population-based studies and a study 
among patients with AD indicate that vascular factors including diabetes mellitus (DM) and 
hypertension may also play a role in MTA.3-5 It is unclear how these factors can lead to MTA. 
There could be a direct effect of the vascular factors resulting in microvascular, metabolic-
toxic or other changes in the medial temporal lobe, which ultimately could result in MTA. 
Alternatively, WMH may be an intermediate in this process: vascular factors cause WMH, 
which in turn may attribute to MTA, possibly by Wallerian degeneration.6,7 
We therefore investigated the association between DM, hypertension and MTA, stratified on 
the severity of WMH in a large group of independently living elderly.  
 
Methods 
The Leukoaraiosis And DISability in the elderly (LADIS) study8 was designed to study the 
influence of WMH on transition to disability, morbidity, mortality and on the quality of life. 
The study is based on a multicenter and multinational collection and follow-up of initially 
non-disabled elderly subjects between 65 and 84 years of age, who were enrolled in 11 
European centers. In order to be included the subjects had to be non-disabled, defined as no 
impairment at all or only one item compromised on the Instrumental Activities of Daily 
Living scale [9], and the MRI had to show some degree of WMH, stratified on the 3 severity 
classes of a revised version of the Fazekas WMH scale.10 Subjects were excluded if they had 
severe illnesses (cardiac, hepatic, or renal failure, cancer or other relevant systemic diseases), 
severe unrelated neurological diseases, leukoencephalopathy of non-vascular origin 
(immunologic-demyelinating, metabolic, toxic, infectious, other), severe psychiatric 
disorders, inability to give an informed consent, or inability or refusal to undergo cerebral 
MRI. For a full description of the sample, we refer to Pantoni et al.8 
At baseline, social background and medical history were assessed through a structured 
interview. A physical exam was performed by a physician. Subjects are currently followed-up 
for 3 years with repeated clinical and MRI studies. The present paper is based on the baseline 
data of the LADIS project. 
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Vascular risk factors 
The history of hypertension, previously assessed by a physician, was collected and reviewed 
during the interview with the aid of a structured questionnaire, and had to be based on 
multiple blood pressure measurements, taken on several separate occasions according to the 
World Health Organization Guidelines for the management of hypertension.22 In these 
guidelines, hypertension is defined as a systolic blood pressure (SBP) of 140 mmHg or 
greater and/or a diastolic blood pressure (DBP) of 90 mmHg or greater in subjects who are 
not taking antihypertensive medication. Also, subjects using antihypertensive medication 
were labeled as hypertensive. If necessary, the family doctor was contacted. In addition to the 
diagnosis of hypertension, the blood pressure was measured once in supine position during 
the baseline examination.  
A history of DM as previously assessed by a physician was based on the internationally 
accepted criteria for DM. These are a 8-hour fasting plasma glucose ≥ 7.0 mmol/L (126 
mg/dL) with symptoms of DM, or two measurements of fasting plasma glucose ≥ 7.0 
mmol/L.23 In addition, a random venous glucose (mmol/l) was measured at the baseline 
examination. Current use of drugs for hypertension (beta-blockers, Ca-antagonisten, ACE 
inhibitors, Alpha2-agonist, angiotensin-antagonist, diuretics, nitrates) and DM were registered 
in a structured way. 
 
MRI 
All subjects were studied by MRI following a standard protocol. MRI scans were made on a 
0.5T (one center) or 1.5T scanner (ten centers) and included at least axial T2-weighted 
images, fluid attenuated inversion recovery (FLAIR) images and a coronal or sagittal T1-
weighted 3D MPRAGE (magnetization prepared rapid acquisition gradient echo) sequence. 
All scans were transferred to the Image Analysis Center (IAC) in Amsterdam, the 
Netherlands, for central data storage. WMH severity was determined on the FLAIR sequence 
using the Fazekas scale:10 the scale includes score 1 (mild: single lesions below 10 mm; areas 
of "grouped" lesions smaller than 20 mm in any diameter), 2 (moderate: single lesions 
between 10 to 20 mm; areas of "grouped" lesions more than 20 mm in any diameter; no more 
than "connecting bridges" between individual lesions) and 3 (severe: single lesions or 
confluent areas of hyperintensity 20 mm or more in any diameter). The sagittal MPRAGE 
  
103
sequences were reformatted to coronal. Medial temporal lobe atrophy was assessed on the 
coronal T1 weighted sequences using the MTA-scale.24 The MTA-scale ranged from 0 to 4: 0 
= no atrophy; 1 = widening of the choroid fissure; 2 = widening of the choroid fissure and the 
temporal horn; 3 = widening of the choroid fissure and temporal horn and diminishing height 
of the hippocampus; 4 = severe atrophy. The mean of the left and right MTA was used in the 
data-analyses. In clinical practice, a score of 0 and 1 is interpreted as normal, and a score of 2-
4 is indicative of atrophy. To determine the intra-rater reliability, 18 scans were scored twice 
for WMH and 15 scans for MTA (weighted Cohen’s kappa for WMH = 0.84 and for MTA = 
0.85).   
 
Statistics  
In the LADIS, a total of 639 subjects were included. Of 56 subjects, the quality of the 
MPRAGE-sequence was insufficient to be read for MTA. Information on vascular factors was 
not available for 1 subject. Therefore 582 subjects were included in the present study. 
Differences between MTA-groups were assessed using analyses of variance for continuous 
data, and chi-square testing for categorical data.   
The relation between blood pressure, hypertension, DM, venous glucose and MTA was 
investigated by multinomial logistic regression. MTA was the dependent variable, with MTA 
= 0 as reference group. Separate models were run for SBP, DBP, hypertension and DM. 
Adjustments were made for age, sex and education (years), as these variables were 
significantly associated with both outcome and risk factors. Data were presented as odds 
ratio’s with accompanying 95% confidence interval (OR (95% CI)) for the 4 MTA-groups. 
The interaction of blood pressure treatment and SBP and DBP was tested with their 
interaction terms in the regression models. Also, the interaction between DM and 
hypertension was tested by their interaction terms in the regression models. To test the 
possible mediating effect of WMH, all models were then run stratified by WMH-severity.  
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Table 1: Demographic Data: The LADIS-Cohort. 
Variable MTA 0 
(n = 126) 
MTA 1 
(n = 287) 
MTA 2 
(n = 123) 
MTA 3 
(n = 40)  
MTA 4 
(n = 6) 
Age (years, mean (SD))* 72.5 (4.8) 74 (5.1) 75.3 (4.7) 76.3 (4.7) 75.4 (4.8) 
Gender (n (%) female) 77 (61.1) 160 (55.7) 59 (48) 11 (36.7) 3 (50) 
Education (years, mean (SD)) 9.8 (4) 9.9 (4.0) 9.2 (3.4) 8.9 (3.7) 7.5 (1.6) 
BP-treatment (n (%)) 67 (53.2) 180 (62.7) 79 (64.2) 23 (57.5) 2 (33.3%) 
Cerebrovascular accidents (n (%)) 26 (20.6) 84 (29.3) 40 (32.5) 14 (35) 3 (50) 
WMH-score (n (%))*      
mild 84 (66.7) 128 (44.6) 30 (24.5) 14 (35) 1 (16.7) 
moderate 28 (22.2) 103 (35.9) 46 (37.4) 6 (15) 1 (16.7) 
severe 14 (11.1) 56 (19.5) 47 (38.2) 20 (50) 4 (66.7) 
Demographic data of LADIS patients included in this study. 
WMH-score according to the WMH scale of Fazekas; MTA = medial temporal lobe atrophy. 
BP-treatment: number of subjects treated for high blood pressure with anti-hypertensive medication (beta-
blockers, Ca-antagonisten, ACE inhibitors, Alpha2-agonist, angiotensin-antagonist, diuretics, nitrates). 
* p < 0.001 
 
Results 
Mean age was 73.5 year (SD = 5.1year), 54% was female. Of the subjects, 15% had DM, and 
70% had hypertension. Of those with DM, 10 were treated with insulin (of which 7 also used 
oral anti-diabetic drugs), 37 with only oral anti-diabetic drugs, and 37 were not treated with 
medication. Subject with DM had similar WMH severity compared to the subjects without 
DM (p = 0.4).  
Subjects with a higher MTA score were older (p < 0.001) and had more WMH (p < 0.001) 
(table 1). There was no association between MTA and sex, education, BP treatment or 
prevalence of cerebrovascular accidents.  
DM was associated with MTA (table 2): subjects with DM had a modestly increased odds for 
MTA score 2 (OR 1.8; CI: 0.9 – 4), and a significantly raised odds for MTA score 3 (OR = 
2.9; 95% CI = 1.1 – 7.8) compared to a MTA score of 0 (no atrophy). No subjects with DM 
had a MTA score of 4. Mean severity of MTA in those treated with insulin, with oral anti-
diabetics and those who were untreated was similar. Stratification on WMH did no show a 
different result, although significance was lost due to small sample size (data not shown). 
There was no significant association between venous glucose and MTA. 
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Table 2: The Association Between Blood Pressure, DM and MTA:  
multinomial logistic regression (n = 582). 
Variable  MTA 0 
(n = 126) 
MTA 1 
(n = 287) 
MTA 2 
(n = 123) 
MTA 3 
(n = 40)  
MTA 4 
(n = 6) 
DM n (%) 13 (10.3) 42 (14.7) 20 (16.5) 9 (23.1) 0 
 OR (95% CI) 1 (ref) 1.5 (0.8-3.0) 1.8 (0.9 – 4) 2.9 (1.1 – 7.8) - 
       
Glucose 
(mmol/l) 
mean (SD) 5.7 (1.6) 5.8 (1.8) 6.1 (1.8) 5.9 (1.7) 5.6 (0.7) 
 OR (95% CI) 1 (ref) 1.0 (0.0-1.2) 1.1 (1-1.3) 1.1 (0.9-1.4) 1 (0.5-2.0) 
       
Hypertension n (%) 83 (65.9) 200 (69.9) 90 (73.2) 27 (67.5) 5 (83.3) 
 OR (95% CI) 1 (ref) 1.3 (0.8–2.0) 1.6 (0.9-2.7) 1.2 (0.6-2.7) 2.6 (0.3-24) 
       
SBP (mmHg) mean (SD) 149 (22) 149 (20) 148 (21) 149 (20) 151 (10) 
 OR (95% CI) 
per 10 mmHg 
1 (ref) 1.0 (0.9-1.1) 1 (0.9-1.1) 1.0 (0.8-1.2) 1.0 (0.7-1.6) 
       
DBP (mmHg) mean (SD) 83 (11) 85 (11) 82 (11) 82 (9) 85 (8) 
 OR (95% CI) 
per 10 mmHg 
1 (ref) 1.2 (0.97-1.5) 0.9 (0.7-1.2) 1.0 (0.7-1.5) 1.2 (0.6-2.6) 
Multinomial logistic regression for the printed variables, with MTA as dependent variable, with MTA 0 as 
reference score. Presented are the OR (95%CI). All models are adjusted for age, sex and education. Separate 
models for separate variables. 
DM = diabetes mellitus; SBP = systolic blood pressure; DBP =  diastolic blood pressure; MTA = medial 
temporal lobe atrophy. 
 
 
SBP and DBP were not associated with MTA (table 2) in the total sample, nor in the 
subsample of subjects with a history of hypertension, nor in the subsample of subjects without 
a history of hypertension (data not shown). Subjects with hypertension had no increased odds 
for MTA (table 2). Stratification on WMH did not alter the associations importantly. There 
was no interaction with anti-hypertensive treatment. No significant interaction of 
hypertension and DM was found. 
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Discussion 
In the present study we found that subjects with DM have a higher risk for MTA compared to 
subjects without DM. Subjects with hypertension did not have an increased risk for MTA. 
The degree of WMH did not modify the results. 
The LADIS study provides a good sample to investigate the influence of vascular factors on 
MTA for several reasons. Principally it consists of non-disabled subjects, who consequently 
have no or only mild cognitive deficits. Therefore, the blood pressure lowering effect of 
dementia25,26 does not come into play. Also, data on treatment of hypertension, age, sex, 
education and DM are collected in a standardised way. In addition, the study was set up to 
include a wide range in severity of WMH among the subjects, so the modifying effect of 
WMH in the association of vascular risk factors and MTA can be studied. 
On the other hand, however, the included subjects do not represent the normal population, but 
are a selection of subjects who were referred to a clinic for several reasons. To be included in 
the LADIS, subjects had to be non- or only mildly disabled. Subjects with severe MTA, who 
are likely to have cognitive defects, were therefore unlikely to be included in the study. This 
is reflected in the fact that 71% of the subjects had no appreciable MTA (score 0 or 1), and 
only 8% had severe MTA (score 3 or 4). Furthermore, because only data from the baseline 
assessment were used in the present study, no effect changes over time could be taken into 
account. 
In the Honolulu Asia Aging study4 and in the Rotterdam study,3 both population based 
longitudinal studies, untreated diastolic hypertension in midlife was associated with 
hippocampal atrophy in late life. Correction for WMH did not change this association. In 
subjects with AD, an association was found between systolic blood pressure and MTA, 
especially in subjects with WMH. This study was cross-sectional, and the effect was small, 
but significant.27 Increased blood pressure is associated with more neurofibrillary tangles and 
neuritic plaques in the hippocampus.28,29 Increased blood pressure could also lead to an 
impaired cerebral blood flow and subsequently damage the hippocampus, especially in the 
ischemia-sensitive CA1 area.30-32 These influences could lead to MTA. Our negative 
observation in this respect is probably caused by sample characteristics: the limitation of 
subject inclusion to non-disabled subjects has inevitably resulted in little variation in MTA. 
Furthermore, it is conceivable that baseline hypertension predicts MTA at follow up.3,4  
Our findings of an association between DM and MTA are in agreement with the Rotterdam 
study5 that reported the volume of the hippocampus to be significantly smaller in subjects 
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with DM, independent of other vascular risk factors. There are several mechanisms that can 
explain the influence of DM on MTA. One of them is through insulin. As in non-insulin 
dependent DM insulin has signalling defects, the inhibitive effect of insulin on 
phosphorylation of tau33 may be diminished. Also, with high insulin levels, insulin degrading 
enzyme will be inhibited to break down amyloid beta.34,35 Another possible mechanism is 
through advanced glycated end products, that is caused by hyperglycemia and may contribute 
to the formation of neurofibrillary tangles and neuritic plaques.36 These processes are known 
to be present in AD, in which disease the medial temporal lobe is primarily affected. 
However, the evidence that DM is importantly associated with MTA is not extensive, and the 
present data are not unambiguously interpretable, as the effect size is small and the number of 
subjects with anti-hyperglycaemic treatment is not large. 
Earlier studies have shown an additive effect of DM and hypertension on vascular morbidity 
and mortality,37 including stroke. In the CASCADE study,38 subjects with DM and 
hypertension had an increased risk for cortical atrophy. Other studies have shown an additive 
effect of DM and hypertension on poor or decline of cognitive function.39,40 These studies all 
suggest that in the presence of both risk-factors the risk of brain damage is higher. Although 
this hypothesis is plausible, our data do not support this, as there was no interaction between 
DM and hypertension.  
The severity of WMH did not influence the association between hypertension, DM and MTA. 
WMH can be a result of hypertension.41-43 In theory, WMH can interrupt neuronal tracts 
projecting from the cortex to the entorhinal cortex and hippocampus, both part of the medial 
temporal lobe. This could cause Wallerian degeneration and subsequently MTA, as was 
suggested in earlier reports.6,7 Our data are not consistent with this theory.  
In conclusion, our study strengthens the observation that MTA is associated with DM, 
independently of the amount of small vessel disease as reflected by WMH. Future research 
should explore the pathological mechanisms more in detail and the influence of strict 
regulation of glucose on the hippocampal volume.  
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Chapter 8 
 
Summary and general discussion 
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This thesis was written to basically explore two questions: 
- Is hippocampal atrophy a good predictor for dementia in subjects with MCI? 
- What are risk factors for hippocampal atrophy? 
 
Chapter 2 
The first question was addressed in chapter 2. 75 subjects with MCI who visited an outpatient 
clinic, underwent MRI as part of the routine clinical examination. After a mean follow-up of 
34 months, 49% were considered demented. The medial temporal lobe atrophy score was 
associated with dementia with a hazard ratio of 1.5 for every point increase in atrophy score 
(p < 0.001), and a hazard ratio of 3.1 for the presence of atrophy based on the dichotomised 
atrophy score (score 0 - 1 vs 2 - 4, p = 0.003). The predictive accuracy of visually assessed 
MTA was independent of age, gender, education, Mini Mental State Examination score, 
Clinical Dementia Rating Sum of Boxes score, verbal delayed recall, the presence of 
hypertension, depression, the APOE-e4 allele and WMH. 
 
The second question was addressed in chapters 3 to 7. 
Chapter 3 
In chapter 3, the relation between blood pressure and hippocampal atrophy was assessed in a 
longitudinal, population based study of Japanese American men (the HAAS). Those never 
treated with anti-hypertensive medication had a significantly increased risk for hippocampal 
atrophy (OR = 1.7). The non-treated subjects with a systolic blood pressure > 140 mmHg at 
midlife had an increased risk (OR = 1.98) for hippocampal atrophy. Results were similar for 
untreated men with a diastolic blood pressure > 90 mmHg at midlife (OR = 3.51). In the 
analyses, we accounted for potential socio-demographic and clinical confounders. These 
variables did not change the found associations. 
 
Chapter 4 
In chapter 4, the association between blood pressure and MTA was assessed in subjects with 
AD, referred to an outpatient clinic. In a linear regression analyses, an association was found 
between pulse pressure (β = 0.08 per 10 mmHg) and systolic blood pressure (β = 0.05 per 10 
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mmHg) and medial temporal lobe atrophy. These associations were particularly found in 
subjects with WMH, and in subjects with a senile onset of AD. 
 
Chapter 5 
In chapter 5, sequential MRIs of 35 subjects with AD from the same outpatient clinic 
population were assessed. MTA and WMH were determined visually. WMH were classified 
subcortical (SCWMH) or periventricular (PVWMH). The mean MTA progression after a 
mean follow-up of 2.2 years was 0.8 for subjects with PVWMH and 0.3 for patients without 
PVWMH at baseline. Subjects with PVWMH at baseline and those with PVWMH-
progression during follow up had a higher risk for MTA and for progression of MTA. This 
was not found for SCWML. 
 
Chapter 6 
In the HAAS, MRI of the brain of subjects with DM were described (chapter 6), with the 
hypothesis that DM leads to both vascular and neurodegenerative changes. The abnormalities 
were compared to the MRI of the brains of those with glucose intolerance and those with 
normal glucose levels. Subjects with DM had more lacunes, smaller hippocampi and more 
generalized atrophy. The risk for both lacunes and small hippocampi was twice as high in 
subjects with DM compared to subjects without DM. 
 
Chapter 7 
In chapter 7, the association of blood pressure and DM with MTA was sought in a large group 
of non-disabled subjects with a wide range of WMH, who visited an outpatient clinic for 
several reasons. Of the subjects, 15% had DM, and 70% had a history of hypertension. 
Subjects with DM had a significantly raised odds ratio for MTA. Systolic and diastolic blood 
pressure and a history of hypertension were not associated with MTA There was no 
interaction between DM and hypertension. Stratification on WMH did not alter the 
associations. 
 
 
 
  
114
General discussion 
 
MTA and MCI 
In the past decade many studies have addressed the issue of MCI, its heterogeneity, and its 
value as being a risk state for dementia. Conflicting results are jeopardizing the longevity of 
the concept of MCI and basically it still exists because of a lack of reliable biological markers 
for AD.  
MCI as such is nothing more than a description of a state with mild cognitive disturbances, 
usually forgetfulness.1 The importance of identifying this syndrome is mainly that it can be an 
early expression of dementia, although studies suggest that up to 40% may never progress to 
dementia.2 On the other hand recognizing those patients that will ultimately fulfill criteria for 
dementia is of utmost importance as soon as treatments become available that may influence 
the rate of progression or stop even the occurrence of full blown dementia syndrome. This is 
currently not possible, but without proper markers these drugs can also not be developed. 
A first attempt to tackle these questions has been made by investigators looking into the value 
of hippocampal atrophy on MRI as a predictor of incipient (present) AD.3-7 We have added to 
that part of the literature the notion that using even a simple visual grading system, the 
presence of hippocampal atrophy triples the chance of developing dementia after 3 years. 
Other studies confirm our finding.3-8 
For clinical trials the MTA score can be used as an inclusion criterion, as the proportion of 
subjects who will convert to dementia should be high. In clinical practice, the MTA score is 
not a sensitive enough marker to use in predicting dementia in the individual, with a 
sensitivity of 70%, a specificity of 68%, and a PPV of 68% and a NPV of 70%. This means 
persons with other than (future) AD also have MTA. Therefore, caution should be taken with 
the interpretation of the score in the individual. Another reason for this prudence is that in old 
age hippocampal volume diminishes.9-14 Maybe the cut-off score for pathology should be 
higher above a certain age, as was recently suggested in a study showing that hippocampal 
volume loss is independently affected by aging and AD.15 Another “false-positive” high 
atrophy score could be caused by hippocampal sclerosis. Sometimes this can be suspected on 
the basis of a higher signal-intensity of the hippocampus on MRI on the proper sequence, but 
usually it is found only on histopathology. 
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In the last few years, the emphasis in MCI is to create subgroups on the basis of cognitive 
performance.16 There are 4 potential subgroups: only memory impaired; one domain not-
memory impaired; multiple domains including memory impaired; multiple domains non-
memory impaired. It is likely that these subgroups have a different prognosis, and that the 
memory-impaired subgroups are better predictors of AD, but this is in part because memory is 
used to diagnose AD. Future studies will clarify the clinical and scientific value of the 
subgroups. It would be interesting to determine the role of the MTA score in predicting 
dementia and AD in these subgroups. 
 
Vascular risk factors and hippocampal atrophy 
The cause of hippocampal atrophy in aging and AD is probably different. Currently, most 
studies suggest that in aging the number of neurons in the hippocampus does not diminish, but 
the neurons probably shrink, thus causing a smaller volume. Also reduction of white matter in 
the hippocampus might attribute to the volume-loss.17-19 In neuropathological studies in AD, 
NFT and NP are pathognomic for AD and thought to be caused by neurodegeneration. 
Neuronal loss is particularly found in the CA1 area and the subiculum.17,19,20 In this thesis, 
high blood pressure and DM are found to be associated with hippocampal atrophy, measured 
either as volume or visually rated, and in subjects with AD as well as in non-demented 
subjects. 
 
Blood pressure and hippocampal atrophy 
High diastolic and systolic blood pressure at midlife increased the risk on hippocampal 
atrophy for those not treated with anti-hypertensive medication (OR 3.5 and 2). In the 
LADIS-study, we could not find an increased risk of high blood pressure for hippocampal 
atrophy; and treatment did not have a modifying effect. The presence or absence of other 
vascular risk factors, vascular co-morbidity or vascular damage on MRI did not change the 
findings in these studies. In subjects with AD, however, an association was found between 
pulse pressure and systolic blood pressure and MTA: for every 10 mmHg increase in pulse-
pressure, the MTA score increased with 0.08 points, and for every 10 mmHg increase in 
systolic blood pressure, the MTA score increased with 0.05. Because this effect is small, it is 
debatable whether these findings are clinically relevant.  
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It has been shown many years ago that subjects with hypertension have more NFT and NP in 
the hippocampus compared to normotensive subjects.21 More recently, a non-significant 
reduced hippocampal volume was found in hypertensive subjects.22 In studies with genetically 
manipulated hypertensive rats,23,24 the hippocampus is atrophied and contains NFT and NP. 
Treatment with anti-hypertensive drugs has a favourable effect on these parameters. In the 
Rotterdam study25 subjects with high diastolic blood pressure, not treated with anti-
hypertensive drugs, had smaller hippocampi. In this study, the follow up was 5 years and the 
age of the subjects 60-90 years. 
Taken together, it is likely that high blood pressure, particularly if not well-controlled, has a 
negative influence on hippocampal volume, but the effect size is not large. The reason for not 
finding robust outcomes in the studies in this thesis might be selection bias. In the HAAS, a 
longitudinal cohort study, all subjects were old. Hypertensive subjects with vascular 
complications, who are likely to die younger, were not included, leaving the relatively more 
healthy subjects in the study. Because of migration, non-participation and death, selection 
could be an issue. There also might be other confounders or effect-modificators that were not 
accounted for, however, based on existing literature no important variables were missed. In 
the LADIS study subjects were younger, but the results presented from this study were cross-
sectional. So, the long-term effect of blood pressure on hippocampal volume could not be 
assessed and causal relations could not be determined. Moreover, the subjects were not 
demented at baseline, thus causing a small range in hippocampal volume. In AD subjects, it is 
known that blood pressure drops with dementia severity.   
The issues mentioned above most likely underestimate the associations we found. 
 
 
The role of WMH 
High blood pressure is associated with WMH.26-28 In the Rotterdam study,26 subjects with 
high blood pressure, and particularly those with long standing hypertension and those with 
poor medication control, had a very high relative risk for WMH. In a sample with 
independently living elderly in Los Angeles,28 an even small raise in blood pressure over 5 
years was associated with more extensive subcortical lesions. Moreover, in the PROGRESS 
study27 the same association was found, and subjects treated for hypertension had less 
progression of the WMH.  
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In theory, WMH could be an intermediate in the relation between high blood pressure and 
hippocampal atrophy. WMH could interrupt the neuronal tracts projecting to the 
hippocampus, causing Wallerian degeneration, and thus causing hippocampal atrophy. The 
study of Bozzali,29 with data from diffusion tensor-MRI, even suggests that WMH in AD are 
likely to be secondary to Wallerian degeneration of fiber tracts due to neuronal loss in cortical 
associative areas. In the HAAS and LADIS we did not find a modifying effect of WMH on 
the association between blood pressure and hippocampal atrophy. In subjects with AD, 
however, the association of high blood pressure and MTA was especially found in subjects 
with WMH. Also, the presence and progression of PVWMH was associated with MTA and 
MTA-progression in subjects with AD.  
The apparent discrepancy between (mainly) non-demented subjects and subjects with AD is 
interesting. It suggests that, in AD, WMH might have a negative effect on hippocampal 
volume, presumably though Wallerian degeneration. In non-demented subjects, however, a 
different aetiology could be present. The CA1 area of the hippocampus is known to be very 
sensitive to ischemia.30,31 High blood pressure causes atherosclerosis and subsequently could 
cause an impaired cerebral blood flow to the CA1 area, ultimately resulting in atrophy. This 
same mechanism is, however, suggested in AD. In 2000, de la Torre32 proposed the 
hypothesis that advanced aging in the presence of vascular risk factor for AD will converge to 
create a ‘Critically Attained Threshold of Cerebral Hypoperfusion’ (CATCH) that will 
subsequently affect the microcirculation and delivery of energy substrates required for 
optimal brain cell function. 
Another explanation for the association between blood pressure and hippocampal atrophy is a 
common agent affecting both separately. Such a common factor could be vasopressin, 
angiotensin converting enzyme, or genetic factors (for review, see Launer33). 
 
Diabetes mellitus and hippocampal atrophy 
Several studies have investigated the association between DM and cognitive impairment and 
dementia, including AD, yielding conflicting results. Recently, a review of population-based 
studies on this subject was published, concluding that subjects with DM have an increased 
risk for dementia, likely including both vascular dementia and AD.34 In 199935 and in 200436 
reviews were published about the studies known to date, and the authors came to the same 
conclusion. Several potential mechanisms have been proposed. In animal studies, it has been 
shown that tasks, dependent on hippocampal function, are performed worse in hyperglycemia, 
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although not all studies confirm this effect (for review, see Messier37). Chronic hyperglycemia 
can affect the efficient transport of nutrients like glucose across the blood brain barrier.38 In 
situations with stress, when cortisol levels increase, the hippocampus of diabetic rats is 
extensively damaged in 1/3 the time compared to the hippocampus of non-DM rats.39  
In hyperglycemia other metabolic processes in DM could directly or indirectly lead to AD-
pathology like NP and NFT. For example, advanced glycated end products can accumulate in 
and cause damage to vascular tissue,38 are found to be present in NFT and senile plaques,40,41 
and are potent neurotoxins. Also, hyperglycemia could lead to microangiopathy, causing 
ischemic damage to the hippocampus, the CA1 area in particular.  
Insulin degrading enzyme (IDE) degrades insuline and β-amyloid, with a preference for 
insulin. In DM, IDE is dysfunctioning, thus causing high levels β-amyloid, which can 
accumulate into senile plaques.42 Hyperinsulinemia is more prevalent in AD, and the activity 
of IDE in the hippocampus is diminished in AD, both causing higher levels of β-amyloid.43,44 
Insulin itself may play an important role. Cerebral insulin signalling is altered in DM. 
Recently, it was found that insulin evokes tau-phosphorylation, especially in the hippocampus 
and hypothalamus.45 Other reports have shown that insulin stimulates β-amyloid secretion, 
and inhibits the extracellular degradation of β-amyloid by competition of insulin degrading 
enzyme.46  
In this respect, it is interesting to mention two hypotheses about the underlying mechanisms 
of the association of DM and AD. In 2001, Brownlee47 suggested that chronic hyperglycemia 
is toxic, either to hippocampal neurons by forming superoxides through metabolism of the 
increased intracellular glucose, or to microvascular endothelial cells, by impairing the blood 
brain barrier and thus impairing the transport of glucose. Recently, Convit39 proposed a 
different model. His theory holds that as insulin resistance influence the blood brain barrier 
for transport of glucose to neurons, and increased cortisol has a negative effect on the 
transport of glucose to the hippocampal neurons, both lead to functional hypoglycaemia, 
causing damage to the hippocampus and thus causing cognitive deficits. 
These hypotheses and the previous data suggest that in DM and possibly also in subjects with 
IGT the hippocampus might be damaged more severely compared to non-DM subjects. 
In this thesis, we investigated the association of DM and hippocampal atrophy in several 
populations. In the studies on subjects with AD, the number of subjects with DM was too 
small to investigate this association. Both in the HAAS and the LADIS, an association was 
found between DM and hippocampal atrophy, although the effect size was not large. 
However, the same limitations apply as for the blood pressure findings (see previous section). 
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Therefore, the results could be an underestimation of reality. A support for this is the fact that 
subjects with DM using insulin, having a longer duration of disease or having disease-related 
complications, had more hippocampal atrophy. Another shortcoming of the presented studies 
is that we did not have a good measure of long-term glucose control, like glycosylated 
haemoglobin A1c. 
 
Diabetes and hypertension 
Earlier studies have found an interaction between DM and hypertension: DM was associated 
with cortical atrophy48 and dementia,49,50 particularly in the presence of high blood pressure. 
In the HAAS, there was no difference in blood pressure between DM, IGT and non-DM, and 
in the regression models SBP did not alter the found associations between DM and 
hippocampal atrophy. In the LADIS, no interaction was found between DM and hypertension. 
As hypertension, particularly not well controlled, was found to be associated with 
hippocampal atrophy (this thesis),25 the blood pressure is a variable that should be accounted 
for. It is possible that hypertension and DM both have an (additional or synergistic) effect on 
the blood brain barrier or on neurodegeneration, thus causing hippocampal atrophy. Future 
studies should explore these options. 
Another possibility is that DM and AD share common (genetic) factors, which facilitate both 
processes. One of them could be APOE e4: Peila et al51 showed that DM, particularly in the 
presence of the APOE ε4, is associated to AD. Also more NFT and cerebral amyloid 
angiopathy was found in subjects with APOE e4 allele. In the HAAS (chapter 6), we included 
the APOE status in the analyses, and did not find a change in the associations.  
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Suggestions for further studies 
 
MCI and hippocampal atrophy 
To further explore the role of hippocampal atrophy in the prediction of dementia, it would be 
interesting to perform a large prospective study on subjects with MCI, and to subdivide this 
sample in memory and non-memory, single and multiple domain MCI, according to 
Petersen.16 At baseline, sociodemographic data like age, education and race, medical data like 
history and medication, neuropsychological tests and a neuropsychiatric questionnaire, APOE 
genotype, cerebrospinal fluid (tau, abeta) and MRI of the brain (MTA, hippocampal volume, 
WMH, lacunes, infarcts) should ideally be performed or determined. Follow up should be as 
long as possible, preferably 6 to 10 years, or until a definite diagnose of dementia and cause 
of dementia is established. The main outcome should be the predicitive effect of hippocampal 
atrophy and MTA on dementia, with determination of the cause of dementia. Secondary 
analyses could be performed to determine the predictive value on dementia of other variables, 
like progression of hippocampal atrophy over time, memory function at baseline and memory 
decline, and baseline cerebrospinal fluid-markers. Therefore, some diagnostic test, like MRI 
and neuropsychological tests, should be repeated during the follow up, maybe every 1-2 year. 
Additionally, it would be interesting to compare the visual and volumetric measures of the 
hippocampus, as an extra validation for the visual score in a large group of subjects, and to 
determine the predictive value for dementia of both measures. As vascular risk factors like 
hypertension and DM have an influence on hippocampal volume and dementia, but also on 
other vascular damage in the brain, and because vascular dementia is based on vascular 
damage, the influence of lacunes, infarcts and WMH should be determined on the outcome of 
dementia. Then it should be possible to validate the subgroups of MCI, and a more useful 
prediction for future patients is possible. These subgroups could be a better basis for 
(farmacological) therapy. 
 
Risk factors for hippocampal atrophy 
To further explore risk factors for hippocampal atrophy, it is necessary to conduct a large, 
population-based, prospective study, with a follow up from midlife (40-50 years) until death. 
The subjects should be a mixture of men and women, several races and social backgrounds. A 
wide number of socio-demographic data should be collected, as well as the medical history, 
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medication and hospital records. MRI of the brain (hippocampal volume, WMH, infarcts, 
atrophy), neuropsychological investigations and preferably cerebrospinal fluid should be 
collected at baseline and after that every five year. Pathological confirmation on diagnoses 
made during life, particularly dementia, should be made. Such as study will need to include a 
substantial number of subjects with vascular risk factors. It would be interesting to evaluate 
the effect on hippocampal volume of a stricter handling of blood glucose and blood pressure. 
Therefore, for these subjects, more regular control of blood pressure and glucose, HbA1c, 
should be performed. 
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Samenvatting 
 
 
De ziekte van Alzheimer (AD) is een veel voorkomende oorzaak van dementie, waarvan de 
diagnose wordt gesteld aan de hand van klinische criteria. AD wordt tevens gekenmerkt door 
hippocampus atrofie. De hippocampus is een onderdeel van de mediale temporaal kwab. 
Atrofie van de mediale temporaal kwab kan beoordeeld worden met een visuele 
beoordelingsschaal, de mediale temporal kwab atrofie (MTA)-schaal volgens Scheltens. Het 
volume van de hippocampus kan met volume-metingen op de MRI-scan bepaald worden. 
Bij mild cognitive impairment (MCI) is er sprake van een cognitieve stoornis in (soms meer 
dan) één domein, waarbij de activiteiten van het dagelijks leven intact zijn. Wanneer dit 
domein het geheugen is, is er sprake van amnestische MCI. Dit kan een eerste klinische uiting 
zijn van AD. Het is van belang de subgroep van mensen met MCI die dement gaat worden, te 
kunnen onderscheiden van de mensen met MCI die niet dement worden, onder andere 
vanwege toekomstige therapiën en wetenschappelijke/farmaceutisch onderzoek. Mogelijk is 
hippocampus atrofie hiervoor een goede voorspeller.   
 
In hoofdstuk 2 worden 75 patiënten met MCI beschreven die een MRI scan ondergaan. 
Hierop wordt de MTA-score bepaald. Na een gemiddelde periode van 34 maanden was 49% 
dement geworden. De MTA score had een hazard ratio voor dementie van 1,5 voor elk punt 
toename in atrofie (p < 0,001), en een hazard ratio van 3,1 voor atrofie gebaseerd op een 
gedichotomoseerde score (score 0-1 vs 2-4, p = 0,003). Deze resultaten zijn onafhankelijk van 
leeftijd, geslacht, opleiding, cognitie-maten (Clinical Dementia Rating schaal, Mini Mental 
State Examination en verbale uitgestelde recall), hypertensie, depressie, het ApoE epsilon4 
allel en witte stof hyperintensiteiten op de MRI. 
 
Hippocampus atrofie bij dementie, vooral AD, wordt gewoonlijk beschouwd als het gevolg 
van neurodegeneratie, waarbij beta-amyloid zich ophoopt tot seniele plaques en het tau-eiwit 
hyperfosforyleert en neurofibrillaire tangles vormt. Uit epidemiologisch onderzoek is naar 
voren gekomen dat vasculaire risicofactoren, zoals hypertensie en diabetes mellitus (DM), een 
risicofactor zijn voor dementie, zowel vasculaire dementie als AD. Ook komen er bij AD 
vaak vasculaire leasies voor op de MRI scan. Al langer is bekend dat een deel van de 
hippocampus gevoelig is voor ischemie.  
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Hieruit volgt onze hypothese dat vasculaire risicofactoren een invloed zouden kunnen hebben 
op het hippocampus volume. In de hoofdstukkken 3 tot en met 7 wordt deze hypothese getest 
in verschillende populaties. 
 
In hoofdstuk 3 is de relatie tussen bloeddruk en hippocampus atrofie onderzocht in een 
longitudinaal, populatie onderzoek onder Japans-Amerikaanse mannen (de Honolulu Asian 
Aging Study (HAAS)). Degenen die niet behandeld werden met anti-hypertensiva hadden een 
significant verhoogd risico op hippocampus atrofie (odds ratio (OR) = 1,7). Degenen met een 
hoge systolische bloeddruk (> 140 mmHg) gedurende middelbare leeftijd die niet behandeld 
werden met anti-hypertensiva, hadden een verhoogd risico op hippocampus atrofie op oudere 
leeftijd (OR = 1,98), evenals degenen met een verhoogde diastolische bloeddruk (> 90 
mmHg) op middelbare leeftijd zonder anti-hypertensiva gebruik (OR = 3,51). Bij de analyses 
werd rekening gehouden met potentiële socio-demografische en klinische verstorende 
factoren. Deze variabelen veranderden de uitkomst van het onderzoek niet.  
In hoofdstuk 4 wordt de relatie tussen bloeddruk en MTA beschreven bij 159 mensen met 
AD. Met lineaire regressie werd een verband gevonden tussen polsdruk (het verschil tussen 
systolisch en diastolische bloeddruk) en MTA (β = 0,08 per 10 mmHg, dit betekent dat per 10 
mmHg stijging in de polsdruk de MTA score 0,08 toeneemt), en systolische bloeddruk en 
MTA (β = 0,05 per 10 mmHg). Deze associaties werden vooral gevonden in degenen met een 
seniele AD, en in degenen met witte stof hyperintensiteiten op de MRI-scan. 
In hoofdstuk 5 gekeken naar de progressie van de witte stofafwijkingen en MTA op MRI met 
behulp van seriële MRI-scans bij 35 mensen met AD. Subcorticale en periventriculaire witte 
stof hyperintensiteiten (SCWMH en PVWMH) en MTA werden visueel beoordeeld op de 
eerste en tweede MRI-scan. Na gemiddeld 2,2 jaar was de progressie in MTA 0,8 voor ptn 
met PVWMH en 0,3 voor degenen zonder PVWMH tijdens de eerste MRI-scan. Degenen met 
PVWMH op de eerste MRI-scan en degenen met PVWMH progressie hadden een hogere 
kans op MTA en MTA-progressie. Voor SCWMH werden geen verschillen gevonden.   
In hoofdstuk 6 wordt de hypothese getoetst of DM zowel degeneratieve als vasculaire 
afwijkingen in de hersenen kan veroorzaken. In de HAAS werden de MRI-scans van Japans-
Amerikaanse mannen met DM vergeleken met MRI-scans van mannen met glucose-
intolerantie, die een hoog risico hebben op DM, en van mannen met een normaal (veneus) 
glucose gehalte. Mannen met DM hadden meer lacunes, kleinere hippocampi en meer 
gegeneraliseerde atrofie. Het risico op lacunes en een kleine hippocampus was 2 maal zo 
groot voor degenen met DM vergeleken met degenen zonder DM. Degenen met glucose-
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intolerantie hadden dezelfde kans op lacunes, infarcten, witte stof hyperintensiteiten en een 
kleine hippocampus als degenen met een normaal glucose. 
In hoofdstuk 7 is het verband tussen DM en bloeddruk met MTA onderzocht in een grote 
groep mensen met een verschillende ernst van witte stof hyperintensiteiten op de MRI-scan. 
Zij bezochten een polikliniek om verschillenden redenen maar functioneerden zelfstandig en 
waren niet dement. Participanten maakten deel uit van de LeukoAraiosis and Disability Study 
(LADIS). 15% van de mensen had DM, 70% had de diagnose hypertensie. Mensen met DM 
hadden een verhoogd risico op MTA (MTA score 3 (ernstige atrofie): OR = 2.9 (95% CI = 
1.1 – 7.8), MTA score 2 (matige atrofie): OR = 1.8 (95% CI = 0.9 – 4), vergeleken met MTA 
score of 0 (= geen atrofie)). Systolische en diastolische bloeddruk en een diagnose hypertensie 
waren niet gerelateerd aan MTA. Er was geen interactie tussen DM en hypertensie. De ernst 
van de witte stof hyperintensiteiten had geen invloed op de uitkomst. 
 
 
Op basis van dit proefschrift kan ten eerste geconcludeerd worden dat MTA een goede 
voorspeller is voor dementie in mensen met MCI. MTA kan een nuttig middel kan zijn voor 
het selecteren van patienten voor wetenschappelijk onderzoek. Ook in de klinische praktijk is 
het een makkelijk toepasbaar middel bij de screening van mensen met milde cognitieve 
stoornissen, alhoewel de MTA score niet sensitief genoeg is om een zekere uitspraak te doen 
over het verdere ziekte-beloop in een individueel geval. 
 
Ten tweede volgt uit de andere hoofdstukken dat DM en hypertensie een negatieve invloed 
hebben op het hippocampus volume. Deze associaties zijn verschillend van sterkte en 
significantie in de verschillende populaties. Tevens is er een effect van (anti-hypertensive en 
anti-diabetische) medicatie en de aanwezigheid witte stof hyperintensiteiten op deze 
associaties. In hoofdstuk 8 wordt hierop ingegaan en worden de mogelijke onderliggende 
pathologische processen belicht.  
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Graag wil ik iedereen bedanken die heeft bijgedragen aan dit boekje. Een aantal mensen wil 
ik in het bijzonder noemen. 
 
Prof. Ph. Scheltens, beste Philip, dank je wel voor de mogelijkheid en de ruimte die je me 
hebt gegeven om te promoveren. Tijdens het sollicitatiegesprek ging je er eigenlijk al vanuit 
dat ik de functie arts-onderzoeker zou accepteren en begon vol enthousiasme te vertellen dat 
het de eerste dag van een geweldig, ander leven was, vol met kansen en mogelijkheden. Daar 
heb je gelijk in gekregen. Je enthousiasme voor wetenschappenlijk onderzoek heb je op mij 
overgedragen, je wist me met je positieve en stimulerende instelling altijd weer uit een 
dalletje te halen, en hebt me de mogelijkheid gegeven om samen te werken met onder andere 
Lenore Launer en Lars-Olof Wahlund. Je staat altijd open voor nieuwe voorstellen, en ik 
kreeg ook de ruimte om deze verder uit te werken. Ik heb veel bewondering voor de manier 
waarop je het Alzheimer centrum in een paar jaar hebt uitgebouwd van praktisch niets tot een 
goedlopende, multidisciplinaire poli met een grote hoeveelheid medewerkers en 
onderzoekers.   
 
Prof. F. Barkhof, beste Frederik, ook jou dank ik voor de mogelijkheid die je me hebt 
geboden om wetenschappelijk onderzoek te doen en te promoveren. Jouw steun en kritische 
blik waren en zijn zeer welkom. Met hulp van het IAC, dat onder jouw leiding staat, heb ik 
vele scans kunnen analyseren. Samen met Philip heb je me laten zien hoe mooi 
wetenschappelijk onderzoek kan zijn.  
 
Doctor Launer, dear Lenore, thank you for the opportunity you gave me to contribute to the 
HAAS. You had to be and were very patient with me, as my statistical and epidemiological 
knowledge was far from adequate when we first met. You taught me a great deal about 
handling a large dataset, and applying the right statistical method to it. You’re persistence and 
determination to never be satisfied with anything less then the best resulted in some beautiful 
articles. I thank you for being my teacher in this respect. I am very pleased to have you as my 
co-promoter. 
 
De overige leden van mij promotie-commissie, prof. Verhey, prof. Mali, prof Heimans, dr. de 
Leeuw en dr. van der Flier, wil ik bedanken voor de aandacht die ze hebben gegeven aan mijn 
proefschrift en het discussiëren over de inhoud tijdens hiervan tijdens de promotie. 
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Prof. Heimans, beste Jan, jij bent degene geweest die me heeft geadviseerd om onderzoek te 
gaan doen, en daar ben ik je erg dankbaar voor. Het was een stap in de juiste richting. Tevens 
dank ik je dat ik de opleiding tot neuroloog in het VUmc onder jou leiding mag volgen. Ik 
waardeer het zeer dat je zo laagdrempelig te benaderen bent, en dat je me tijdens de opleiding 
de ruimte hebt gegeven om mijn promotie af te ronden. 
 
Laura en Lydia, mijn paranimfen, veel dank voor jullie steun in de laatste fase van mijn 
promotie. Jullie steun en positieve instelling hebben mij geholpen de lol in te blijven zien van 
een promotie en alle voorbereidingen die hiervoor nodig zijn: nog even de laatste 
hoofdstukken schrijven, boekje lay-outen, lokatie uitzoeken, etc, etc. Zonder jullie was het me 
vast niet gelukt het te laten lopen zoals het nu gelopen is. Laura, ik vind het geweldig dat jij 
het onderzoek naar de hippocampus hebt “overgenomen”. Ik heb veel respect voor de manier 
waarop je dat doet, je bent altijd zeer enthousiast en tegelijkertijd kritisch. Ik weet zeker dat 
jouw boekje, wat op korte termijn toch klaar zal zijn, er prachtig uit komt te zien en dat je 
jouw promotie tot een goed einde zal brengen. Lydia, ik dank je voor je niet-aflatende 
vriendschap en steun. Laten we vrijdag weer koffie drinken… 
 
Wiesje, Pieter-Jelle en Frank-Erik, jullie hebben me onder andere bijgestaan met jullie 
statistische kennis. Samen hebben we een aantal mooie artikelen geschreven. Mijn dank voor 
jullie steun en enthousiasme. 
 
Mijn ex-kamergenoten, Peter, Lisa, Niki en Maaike, jullie wil ik bedanken voor jullie 
gezelligheid en opbeurende gesprekken, in de soms wat nauwe, raamloze, kamers. Samen met 
de andere onderzoekers hadden we een leuke, gezellige groep. 
 
Alle medewerkers van het IAC, in het bijzonder Tineke, Michel en Marieke, de 
baliemedewerkers en verpleging (Ina, Marijke) van de polikliniek neurologie, bedankt voor 
jullie hulp bij het uitvoeren van de onderoeken. Beste Els van Deventer, veel dank voor jou 
hulp bij het zoeken naar uiteindelijk toch vindbare artikelen. 
 
Dr Joe Frank and his lab, thank you for lending me a place to sit and a computer for 
measuring a numerous amount of hippocampi! You were all very kind to me, helping me out 
with the software and feeding me cake on birthdays. Also thanks to the co-workers of Lenore, 
especially Ann, Caroline and Joanne. Your hospitality was very welcome, you helped me out 
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if possible, arranged a house for us to live in, and even took me to a basketball game. You 
made my weeks in America more pleasant. 
 
Als laatste, en belangrijkste, wil ik mijn familie bedanken. Allereerst mijn ouders, die mijn 
studie geneeskunde mogelijk hebben gemaakt. Zij hebben me altijd gesteund, net als mijn 
schoonouders, al was het niet makkelijk om de (schoon)dochter, (schoon)zoon, en vooral 2 
kleinkinderen een half jaar te moeten missen. Herman, Anne en Bram, jullie hebben heel wat 
te stellen met me. Ik dank jullie vooral voor jullie liefde en geduld. Ik hou van jullie. 
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